Document:

Exhibit
10.9

 

[*]
Certain information in this document has been omitted from this exhibit because it is both (i) not material and

 (ii) would
be competitively harmful if publicly disclosed.

 

The
George Washington University

 

Patent
License Agreement

 

This
Patent License Agreement (this “Agreement”) is between the George Washington University, a congressionally
chartered not-for-profit corporation (“University”) located in the District of Columbia, and Hoth Therapeutics
Inc., a Nevada corporation having offices at One Rockefeller Plaza, Suite 1039, New York, NY 10020 (“Company”).
This Agreement is being signed on August 7, 2020 (the “Execution Date”). This Agreement will become effective
as of August 7, 2020 (the “Effective Date”).

 

BACKGROUND

 

University
owns certain intellectual property developed by Professor Mona Zaghloul of the University’s School of Engineering &
Applied Sciencese and Professor Jean A. Jordan of the University’s School of Public Health relating to the Nanohole-Array
Based Sensors technology corresponding to University’s intellectual property docket numbers [*] and [*]. University also
owns certain letters patent and/or applications for letters patent relating to the intellectual property. Company desires to obtain
an exclusive license under the patent rights to exploit the intellectual property. Company also desires to fund further research
by Professor Mona Zaghloul and Professor Jean Jordan under a separate agreement. University has determined that the exploitation
of the intellectual property by Company is in the best interest of University and is consistent with its educational and research
missions and goals.

 

In
consideration of the mutual obligations contained in this Agreement, and intending to be legally bound, the parties agree as follows:

 

		1.	LICENSE

 

1.1
License Grant. University grants to Company a license (the “License”) according to the exclusivity and
territory terms described in Appendix A to make, have made, use, import, offer for sale and sell Licensed Products in the Field
of Use during the Term (as such terms may be defined in Sections 1.2, 6.1, Appendix A). The License includes the right to sublicense
as permitted by this Agreement. No other rights or licenses are granted by University.

 

    Page 1 of 24

     

    

 

1.2
Related Definitions. The term “Licensed Products” means products and services that are made, made for,
used, imported, offered for sale or sold by Company or its Affiliates or sublicensees and that would (i) in the absence of the
License, infringe (or, in the case of pending patent applications, upon issuance, would infringe) at least one claim of the Patent
Rights or (ii) use a process or machine covered by a claim of Patent Rights, whether the claim is issued or pending. The term
“Sublicense” means an arms-length transaction pursuant to which Company grants an unrelated third party access
to Patent Rights and/or Technology. Any delivery of Licensed Products to an End User via an Application Program Interface (API)
shall be considered a Sale of Licensed Product. Under the License Agreement, University will agree that End User License Agreements
will not be treated as sublicenses. The term “Patent Rights” means all of University’s patent rights represented
by or issuing from: (a) the United States patents and patent applications listed in Exhibit A; (b) any continuation, divisional
and re-issue applications of (a); and (c) any foreign counterparts and extensions of (a) or (b). The term “Affiliate”
means a legal entity that is controlling, controlled by or under common control with Company and that has executed either this
Agreement or a written Joinder Agreement agreeing to be bound by all of the terms and conditions of this Agreement. For purposes
of this Section 1.2, the word “control” means (x) the direct or indirect ownership of more than fifty percent
(50%) of the outstanding voting securities of a legal entity, (y) the right to receive fifty percent (50%) or more of the profits
or earnings of a legal entity, or (z) the right to determine the policy decisions of a legal entity. The term “Field
of Use” means the definition agreed to in Appendix A.

 

1.3
Reservation of Rights by University. University reserves the right to use, and to permit other non-commercial entities to
use, the Patent Rights for educational and research purposes.

 

1.4
U.S. Government Rights. The parties acknowledge that the United States government retains rights in intellectual property
funded under any grant or similar contract with a Federal agency. The License is expressly subject to all applicable United States
government rights, including, but not limited to, any applicable requirement that products, which result from such intellectual
property and are sold in the United States, must be substantially manufactured in the United States.

 

1.5
Sublicense Conditions. The Company’s right to sublicense granted by University under the License is subject to each
of the following conditions:

 

(a) In
each sublicense agreement, Company will prohibit the sublicensee from further sublicensing and require the sublicensee to comply
with the terms and conditions of this Agreement.

 

(b) Within
thirty (30) days after Company enters into a sublicense agreement, Company will deliver to University a complete and accurate
copy of the entire sublicense agreement written in the English language. University’s receipt of the sublicense agreement,
however, will constitute neither an approval of the sublicense nor a waiver of any right of University or obligation of Company
under this Agreement.

 

(c) In
the event that Company causes or experiences a Trigger Event (as defined in Section 6.4), all payments due to Company from its
Affiliates or sublicensees under the sublicense agreement will, upon notice from University to such Affiliate or sublicensee,
become payable directly to University for the account of Company. Upon receipt of any such funds, University will remit to Company
the amount by which such payments exceed the amounts owed by Company to University.

 

(d) Company’s
execution of a sublicense agreement will not relieve Company of any of its obligations under this Agreement, including its obligation
to use commercially reasonable efforts to develop, commercialize, market and sell Licensed Products in a manner consistent with
the Development Plan. Company is primarily liable to University for any act or omission of an Affiliate or sublicensee of Company
that would be a breach of this Agreement if performed or omitted by Company, and Company will be deemed to be in breach of this
Agreement as a result of such act or omission.

 

    Page 2 of 24

     

    

 

No
License by Implication. Nothing in this Agreement confers by estoppel implication or otherwise, any license or rights under
any University patent other than the Patent Rights, regardless whether such patents are dominant or subordinate to the Patent
Rights.

 

		2.	DILIGENCE

 

2.1
Development Plan. Company will deliver to University, within ninety (90) days after the Effective Date, a copy of an
initial development plan for the Patent Rights (the “Development Plan”). The purpose of the Development
Plan is (a) to demonstrate Company’s capability to bring the Patent Rights to commercialization, (b) to project the
timeline for completing the necessary tasks, and (c) to measure Company’s progress against the projections. Thereafter,
Company will deliver to University an annual updated Development Plan no later than December 1 of each year during the Term.
The Development Plan will include, at a minimum, the information listed in Exhibit B. Company will use commercially
reasonable efforts to develop, commercialize, market and sell Licensed Products in a manner consistent with the written
Development Plan.

 

2.2
Diligence Events. The Company will use commercially reasonable efforts to achieve each of the diligence events by the applicable
completion date listed in Appendix A. In addition to usual and reasonable terms for termination, the University reserves the right
to terminate the Agreement if Company fails to achieve one or more diligence events on or before their respective achievement
date.

 

2.3
Diligence Resources. Until the first commercial sale of the first Licensed Product, Company will expend resources in the development
and commercialization of the Licensed Products of amounts not less than the diligence minimums specified in Appendix A in each
12-month period following the Effective Date. If Company’s total expenditures for development and commercialization of Licensed
Products in any 12-month period do not meet or exceed the applicable diligence minimum, then Company will pay to University the
amount of the shortfall. Company will make any payments of the shortfall to University together with the next Development Plan
due to University under Section 2.1.

 

		3.	FEES
AND ROYALTIES

 

3.1
License Initiation Fee. In partial consideration of the License, Company will pay to University no later than 30 days from
the Effective Date a non-refundable, non-creditable license initiation fee as specified in Appendix A.

 

3.2
Equity Issuance. In partial consideration of the License, Company will issue warrants to University no later than 30 days
from the Effective Date, to purchase the amount of shares of Company that can be bought for $200,000 at the strike price per share
at the time of warrant issuance. The University’s warrants will vest on the following schedule: 20% at issuance, 20% each year
thereafter, resulting in 100% vesting 4 years after issuance. The University’s warrants will have an expiration date 10 years
or later from the date of issuance.

 

    Page 3 of 24

     

    

 

3.3
Dilution Protection. Intentionally omitted.

 

3.4
Follow-On Investments. Intentionally omitted.

 

3.5
License Maintenance Fees. In partial consideration of the License, Company will pay to University, on each anniversary
of the Effective Date until the first Sale (as defined in Section 3.8) of the first Licensed Product, the applicable license maintenance
fee listed in Appendix A.

 

3.6
Milestone Payments. In partial consideration of the License, Company will pay to University the applicable milestone payment
listed in Appendix A after achievement of each milestone event for each Licensed Product. Company will provide University with
written notice within thirty (30) days after achieving each milestone.

 

For
clarity, each time a milestone is achieved with respect to a Licensed Product, then any other milestone payments with respect
to earlier milestones that have not yet been paid will be due and payable together with the milestone payment for the milestone
that is actually achieved.  For additional clarity, milestones are due and payable on Licensed Products and on products that,
upon FDA approval, would become Licensed Products. 

 

3.7
Earned Royalties. In partial consideration of the License, Company will pay to University a royalty as specified in Appendix
A during the Quarter.

 

3.8
Related Definitions. The term “Sale” means any bona fide transaction for which consideration is received
by Company or its Affiliate or sublicensee for the sale, use, lease, transfer or other disposition of a Licensed Product to a
third party. A Sale is deemed completed at the time that Company or its Affiliate or sublicensee invoices, ships or receives payment
for a Licensed Product, whichever occurs first. The term “Quarter” means each three-month period beginning
on January 1, April 1, July 1 and October 1. The term “Net Sales” means the consideration received or expected
from, or the fair market value attributable to, each Sale, less Qualifying Costs that are directly attributable to a Sale, specifically
identified on an invoice or other documentation and actually borne by Company or its Affiliates or sublicensees. For purposes
of determining Net Sales, the words “fair market value” means the cash consideration that Company or its Affiliates
or sublicensees would realize from an unrelated buyer in an arm’s length sale of an identical item sold in the same quantity
and at the time and place of the transaction. The term “Qualifying Costs” means: (a) customary discounts in
the trade for quantity purchased or for wholesalers and distributors; (b) credits or refunds for claims or returns that do not
exceed the original invoice amount; (c) prepaid outbound transportation expenses and transportation insurance premiums; and (d)
sales and use taxes and other fees imposed by and indefeasibly paid to a governmental agency.

 

3.9
Minimum Royalties. In partial consideration of the License, Company will pay on a Quarterly basis to University the applicable
minimum royalty listed in Appendix A, if Company’s actual earned royalties under Section 3.7 for each Quarter after the first
Sale of a Licensed Product does not exceed this amount.

 

    Page 4 of 24

     

    

 

3.10
Sublicense Fees. In partial consideration of the License, Company will pay to University a sublicense fee specified in Appendix
A of the sum of all payments plus the fair market value of all other consideration of any kind, received by Company from sublicensees
during the Quarter, excluding: (a) royalties paid to Company by a sublicensee based upon Sales or Net Sales by the sublicensee;
(b) equity investments in Company by a sublicensee up to the amount of the fair market value of the equity purchased on the date
of the investment; (c) loan proceeds paid to Company by a sublicensee in an arm’s length, full recourse debt financing to
the extent that such loan is not forgiven; and (d) sponsored research funding paid to Company by a sublicensee in a bona fide
transaction for future research to be performed by Company.

 

		4.	REPORTS
AND PAYMENTS

 

4.1
Royalty Reports. Within forty-five (45) days after the end of each Quarter following the first Sale, Company will deliver
to University a report, certified by the chief financial officer of Company, detailing the calculation of all royalties, fees
and other payments due to University for such Quarter. The report will include, at a minimum, the following information for the
Quarter, each listed by product, by country: (a) the number of units of Licensed Products constituting Sales; (b) the gross consideration
invoiced, billed or received for Sales; (c) Qualifying Costs, listed by category of cost; (d) Net Sales; (e) the gross amount
of any payments and other consideration received by Company from sublicensees and the amounts of any deductions permitted by Section
3.8; (f) the royalties, fees and other payments owed to University, listed by category; and (g) the computations for any applicable
currency conversions. Each royalty report will be substantially in the form of the sample report attached as Exhibit C.

 

4.2
Payments. Company will pay all royalties, fees and other payments due to University under Sections 3.6, 3.7, 3.8, 3.10 within
forty-five (45) days after the end of the Quarter in which the royalties, fees or other payments accrued.

 

4.3
Records. Company will maintain, and will cause its Affiliates and sublicensees to maintain, complete and accurate books, records
and related background information to verify Sales, Net Sales, and all of the royalties, fees, and other payments due or paid
under this Agreement, as well as the various computations reported under Section 4.1. The records for each Quarter will be maintained
for at least five (5) years after submission of the applicable report required under Section 4.1.

 

4.4
Audit Rights. Upon reasonable prior written notice to Company, Company and its Affiliates and sublicensees will provide University
and its accountants with access to all of the books, records and related background information required by Section 4.3 to conduct
a review or audit of Sales, Net Sales, and all of the royalties, fees, and other payments payable under this Agreement. Access
will be made available: (a) during normal business hours; (b) in a manner reasonably designed to facilitate University’s
review or audit without unreasonable disruption to Company’s business; and (c) no more than once each calendar year during
the Term (as defined below) and for a period of five (5) years thereafter. Company will pay to University within 45 days the amount
of any underpayment determined by the review or audit, plus accrued interest. If the review or audit determines that Company has
underpaid any payment by five percent (5%) or more, then Company within 45 days will also pay the costs and expenses of University
and its accountants in connection with the review or audit.

 

4.5
Information Rights. Company will provide to University, promptly after filing, a copy of each annual report, proxy statement,
10-K, 10-Q and other material report filed with the U.S. Securities and Exchange Commission.

 

    Page 5 of 24

     

    

 

4.6
Currency. All dollar amounts referred to in this Agreement are expressed in United States dollars. All payments will be made
in United States dollars. If Company receives payment from a third party in a currency other than United States dollars for which
a royalty or fee is owed under this Agreement, then (a) the payment will be converted into United States dollars at the conversion
rate for the foreign currency as published in the eastern edition of the Wall Street Journal as of the last business day of the
Quarter in which the payment was received by Company, and (b) the conversion computation will be documented by Company in the
applicable report delivered to University under Section 4.1.

 

4.7
Place of Payment. All payments by Company are payable to “The George Washington University” and will be made to
the following addresses:

 

	By
                                         Check:

         

	The
                                         George Washington University

        c/o
        Technology Commercialization Office

        1922
        F ST NW, 4TH Floor

        Washington,
        DC 20052

         

        Attention:
        TCO Operations Coordinator

         

	By
                                         Electronic Transfer:

         

        For
        Patent Cost Reimbursements please include: 

        “Funds
        should be credited to Alias 111406, Account”

         

        For
        License Fees and Royalties please include: 

        “Funds
        should be credited to Alias 100035, Account”

         

	Beneficiary
                                         Account Number:

        Beneficiary
        Account Type (for ACH):

        Beneficiary
        Account Name:

        Beneficiary
        Address:

         

         

        Bank’s
        Name:

        Bank’s
        Address:

         

        ABA
        # (for ACH):

        ABA
        # (for Wires):

        SWIFT:
	Checking

        The
        George Washington University

        1918
        F ST NW

        Washington,
        DC 20052

         

        PNC
        Bank, N.A.

        800
        17th ST, NW

        Washington,
        DC 20006

        PNCCUS33

 

4.8
Interest. All amounts that are not paid by Company when due will accrue interest from the date due until paid at a rate equal
to one and one-half percent (1.5%) per month (or the maximum allowed by law, if less). The payment of such interest shall not
foreclose University from exercising any other rights it may have as a consequence of the lateness of any payment.

 

    Page 6 of 24

     

    

 

		5.	CONFIDENTIALITY
AND USE OF UNIVERSITY’S NAME

 

5.1
Confidentiality. Except as specifically permitted hereunder Parties hereby agree to hold in confidence and not use on behalf
of itself or others all technology, data, samples, technical and economic information (including economic terms hereof), commercialization,
clinical and research strategies, know-how and trade secrets provided by the other party (the “Disclosing Party”) (collectively
the “Confidential Information”), except that the term “Confidential Information” shall not include:

 

		(a)	information
that is or becomes part of the public domain through no fault of the non-Disclosing Party;

 

		(b)	information
that is obtained after the Effective Date by the non-Disclosing Party or one of its Affiliates from any third party which is lawfully
in possession of such Confidential Information and not in violation of any contractual or legal obligation to the Disclosing Party
with respect to such Confidential Information;

 

		(c)	information
that is known to the non-Disclosing Party or one or more of its Affiliates prior to the disclosure by the Disclosing Party, as
evidenced by the non-Disclosing Party’s written records; and

 

		(d)	information
which has been independently developed by the non-Disclosing Party without the aid or use of Confidential information as shown
by competent written evidence.

 

The
party receiving the Confidential Information may disclose the Disclosing Party’s proprietary information to the extent required
to comply with, a court or administrative subpoena or a lawful court order provided that the receiving party first uses its best
efforts to obtain an order preserving the confidentiality of the information of the Disclosing Party and provided the receiving
party gives the Disclosing Party timely notice of the contemplated disclosure to give the Disclosing Party an opportunity to intervene
to preserve the confidentiality of the information.

 

Upon
prior review of the University, Company may disclose in a patent application or the prosecution thereof, any Confidential Information
necessary to obtain or secure patent protection of the commercialized products or processes.

 

Each
Party intends that to the extent that any confidential information is disclosed under this Agreement, such Confidential Information
does not contain export control-listed technology or technical data identified on any US export control list, including the Commerce
Control List (CCL) set forth in the Export Administration Regulations at 15 CFR Part 774 and the US Munitions List (USML) set
forth in the International Traffic in Arms Regulations at 22 CFR Part 121. Prior to one Party providing the other Party with export
control-listed information, the disclosing Party will provide advance written notice to the receiving Party regarding the export
classification of such information, and the receiving Party must issue written approval to the disclosing Party prior to the transmission
of such information to the receiving Party. Notwithstanding any other provision of this Agreement, the receiving Party is under
no obligation to accept export control-listed information from the disclosing Party.

 

    Page 7 of 24

     

    

 

5.2
Use of University’s Name. Company and its Affiliates, sublicensees, employees, and agents may not use the name, logo, seal,
trademark, or service mark (including any adaptation of them) of University or any University school, organization, employee,
student or representative, without the prior written consent of University.

 

		6.	TERM
AND TERMINATION

 

6.1
Term. This Agreement will commence on Effective Date and terminate upon the later of: (a) the expiration or abandonment of
the last patent to expire or become abandoned of the Patent Rights; or (b) ten (10) years after the first Sale of the first Licensed
Product if no patent has issued from the Patent Rights (as the case may be, the “Term”).

 

6.2
Early Termination by Company. Company may terminate this Agreement at any time effective upon completion of each of the following
conditions: (a) providing at least sixty (60) days prior written notice to University of such intention to terminate; (b) ceasing
to make, have made, use, import, offer for sale and sell all Licensed Products; (c) terminating all sublicenses and causing all
Affiliates and sublicensees to cease making, having made, using, importing, offering for sale and selling all Licensed Products;
and (d) paying all amounts owed to University under this Agreement between University and Company related to the Patent Rights,
through the effective date of termination.

 

6.3
Early Termination by University. University may terminate this Agreement if: (a) Company is more than thirty (30) days late
in paying to University any amounts owed under this Agreement and does not immediately pay University in full, including accrued
interest, upon demand (a “Payment Default”); (b) other than a Payment Default, Company or its Affiliate or sublicensee
breaches this Agreement and does not cure the breach within forty-five (45) days after written notice of the breach; or (c) Company
or its Affiliate or sublicensee experiences a Trigger Event.

 

6.4
Trigger Event. The term “Trigger Event” means any of the following: (a) a material default by Company under
any Agreement between Company and University related to the Patent Rights (whether entered prior to, contemporaneous with, or
subsequent to the Effective Date) any Sponsored Research Agreement between Company and University related to the Patent Rights
(whether entered prior to, contemporaneous with, or subsequent to the Effective Date, any of the Equity Documents, or this Agreement,
that is not cured during any specified cure periods; (b) if Company or its Affiliate or sublicensee (i) becomes insolvent, bankrupt
or generally fails to pay its debts as such debts become due, (ii) is adjudicated insolvent or bankrupt, (iii) admits in writing
its inability to pay its debts, (iv) suffers the appointment of a custodian, receiver or trustee for it or its property and, if
appointed without its consent, not discharged within thirty (30) days, (v) makes an assignment for the benefit of creditors, or
(vi) suffers proceedings being instituted against it under any law related to bankruptcy, insolvency, liquidation or the reorganization,
readjustment or release of debtors and, if contested by it, not dismissed or stayed within ten (10) days; (c) the institution
or commencement by Company or its Affiliate or sublicensee of any proceeding under any law related to bankruptcy, insolvency,
liquidation or the reorganization, readjustment or release of debtors; (d) the entering of any order for relief relating to any
of the proceedings described in Section 6.4(b) or (c) above; (e) the calling by Company or its Affiliate or sublicensee of a meeting
of its creditors with a view to arranging a composition or adjustment of its debts; (f) the act or failure to act by Company or
its Affiliate or sublicensee indicating its consent to, approval of or acquiescence in any of the proceedings described in Section
6.4(b) – (e) above; (g) the commencement by Company of any action against University, including an action for declaratory
judgment, to declare or render invalid or unenforceable the Patent Rights, or any claim thereof.

 

    Page 8 of 24

     

    

 

6.5
Effect of Termination. Upon the termination of this Agreement for any reason: (a) the License terminates; (b) Company and
all its Affiliates and sublicensees will cease all making, having made, using, importing, offering for sale and selling all Licensed
Products, except to extent permitted by Section 6.6; (c) Company will pay to University all amounts, including accrued interest,
owed to University under this Agreement and any Sponsored Research Agreement related to the Patent Rights, through the date of
termination, including royalties on Licensed Products invoiced or shipped through the date of termination and any sell off period
permitted by Section 6.6, whether or not payment is received prior to termination or expiration of the sell off period permitted
by Section 6.6; (d) Company will, at University’s request, return to University all confidential information of University
and provide to University one complete copy of all data with respect to Licensed Products generated by Company during the Term
that will facilitate the further development of the technology licensed under this Agreement; and (e) in the case of termination
under Section 6.3, all duties of University and all rights (but not duties) of Company under this Agreement immediately terminate
without further action required by either University or Company.

 

6.6
Inventory & Sell Off. Upon the termination of this Agreement for any reason, Company will cause physical inventories to
be taken immediately of: (a) all completed Licensed Products on hand under the control of Company or its Affiliates or sublicensees;
and (b) such Licensed Products as are in the process of manufacture and any component parts on the date of termination of this
Agreement. Company will deliver promptly to University a copy of the written inventory, certified by an officer of the Company.
Upon termination of this Agreement for any reason, Company will promptly remove, efface or destroy all references to University
from any advertising, labels, web sites or other materials used in the promotion of the business of Company or its Affiliates
or sublicensees, and Company and its Affiliates and sublicensees will not represent in any manner that it has rights in or to
the Patent Rights or the Licensed Products. Upon the termination of this Agreement for any reason other than pursuant to Section
6.3(a) or (c), Company may sell off its inventory of Licensed Products existing on the date of termination for a period of six
(6) months and pay University royalties on Sales of such inventory within thirty (30) days following the expiration of such six
(6) month period.

 

6.7
Survival. Company’s obligation to pay all amounts, including accrued interest, owed to University under this Agreement
will survive the termination of this Agreement for any reason. Sections 14.10 and 14.11 and Articles 4, 5, 6, 9, 10, and 11 will
survive the termination of this Agreement for any reason in accordance with their respective terms.

 

		7.	PATENT
PROSECUTION AND MAINTENANCE

 

7.1
Patent Control.  University controls the preparation, prosecution and maintenance of the Patent Rights and the selection of
patent counsel, with input from Company. For purposes of this Article 7, the word “maintenance” includes any
interference negotiations, claims, or proceedings, in any forum, brought by University, Company, a third party, or the United
States Patent and Trademark Office, and any requests by University or Company that the United States Patent and Trademark Office
reexamine or reissue any patent in the Patent Rights.

 

    Page 9 of 24

     

    

 

7.2
Payment and Reimbursement. Company agrees that the University has incurred historically accrued attorney fees, expenses, official
fees and all other charges accumulated and invoiced to the University incident to the preparation, filing, prosecution and maintenance
of the Patent Rights (the “Past Patent Expenses”) as specified in Appendix A. By the Past Patent Expenses Reimbursement
Date identified in Appendix A, Company will reimburse University for Past Patent Expenses. For patent expenses not included in
Appendix A, including, but not limited to those incurred during the Term, Company will either pay directly under a Client and
Billing Agreement or reimburse University for all documented attorneys’ fees, expenses, official fees and all other charges
accumulated or invoiced to the University incident to the preparation, filing, prosecution, and maintenance of the Patent Rights,
within thirty (30) days after Company’s receipt of invoices for such fees, expenses and charges. University reserves the right
to require the Company to provide a deposit in advance of incurring out of pocket patent expenses estimated by counsel to exceed
$2,500. If Company fails to reimburse patent expenses under Paragraph 7.2, or provide a requested deposit with respect to a Patent
Right, then University will be free at its discretion and expense to either abandon such applications or patents related to such
Patent Right or to continue such preparation, prosecution and/or maintenance activities and to the extent University has pursued
protection of any patent rights associated with such patent action will remain subject to the license granted under this Agreement.
Any abandonment of patents or applications under Patent Rights by the University shall not affect Company’s obligation to pay
prior royalties due under this Agreement that were accrued prior to the date of abandonment of patents or applications for such
the Patent Rights.

 

7.3
Patent Marking. Company shall include appropriate marking on all Licensed Products made, sold or otherwise disposed of by
Company, which patent marking will be in accordance with appropriate patent marking laws of the United States and any other country
in which such the Licensed Products are made, sold or otherwise disposed of. Company will cause its Affiliates and/or sublicensees
to similarly mark any Licensed Products made, sold or otherwise disposed of by such Affiliates or sublicensees.

 

		8.	INFRINGEMENT

 

8.1
Notice. Company and University will notify each other promptly, but in no event later than five days of any infringement of
the Patent Rights that may come to their attention. Company and University will consult each other in a timely manner concerning
any appropriate response to the infringement.

 

8.2
Prosecution of Infringement. Company may prosecute any infringement of the Patent Rights at Company’s expense, including
defending against any counterclaims or cross claims brought by any party against Company or University regarding the Patent Rights
and defending against any claim that the Patent or Patent Rights are invalid in the course of any infringement action or in a
declaratory judgment action. University reserves the right to intervene voluntarily and join Company in any such infringement
litigation. If University chooses not to intervene voluntarily, but University is a necessary party to the action brought by Company,
then Company may join University in the infringement litigation. If Company decides not to prosecute any infringement of the Patent
Rights, then University may elect to prosecute such infringement independently of Company in University’s sole discretion.

 

    Page 10 of 24

     

    

 

8.3
Cooperation. In any litigation under this Article 8, either party, at the request and sole expense of the other party, will
cooperate to the fullest extent reasonably possible. This Section 8.3 will not be construed to require either party to undertake
any activities, including legal discovery, at the request of any third party, except as may be required by lawful process of a
court of competent jurisdiction. If, however, either party is required to undertake any activity, including legal discovery, as
a right of lawful process of a court of competent jurisdiction, then Company will pay all expenses incurred by Company and by
University.

 

8.4
Control of Litigation. Company controls any litigation or potential litigation involving the prosecution of infringement claims
regarding the Patent Rights in which University is not a party, including the selection of counsel, all with input from University.
Company must not settle or compromise any such litigation in a manner that imposes any obligations or restrictions on University
or grants any rights to the Patent Rights, other than any permitted sublicenses, without University’s prior written permission.
University controls any litigation or potential litigation involving the prosecution of infringement claims regarding the Patent
Rights in which University has elected to prosecute the infringement independently of Company or has voluntarily or involuntarily
joined Company in the infringement litigation, including the selection of counsel, all with input from Company. In all instances
in which University is a party, University reserves the right to select its own counsel. If University is involuntarily joined
as a party, University retains the right to select its own counsel, but Company will be responsible for all litigation expenditures
as set forth in Section 8.5.

 

8.5
Recoveries from Litigation. If Company prosecutes any infringement claims either without University as a party or with University
involuntarily joined as a party, then Company will reimburse University for University’s litigation expenditures, including
any attorneys’ fees, expenses, official fees and other charges incurred by University, even if there are no financial recoveries
from the infringement action. Company will reimburse University within thirty (30) days after receiving each invoice from University.
After reimbursing University for its expenditures, Company will use the financial recoveries from such claims, if any, (a) first,
to reimburse Company for its litigation expenditures; and (b) second, to retain any remainder but to treat the remainder as either
(i) Net Sales for the purpose of determining the royalties due to University under Section 3.7 or (ii) sublicense consideration
for the purpose of determining the sublicense fees due to University under Section 3.10, whichever would result in a larger payment
to University. If Company prosecutes any infringement claims with University joined as a voluntary party, then any financial recoveries
from such claims will be (x) first, shared between Company and University in proportion with their respective shares of the aggregate
litigation expenditures by Company and University; and (y) second, shared equally by Company and University as to any remainder
after Company and University have fully recovered their aggregate litigation expenditures. If University prosecutes any infringement
claims independent of Company, then University will prosecute such infringement at University’s expense and will retain
any financial recoveries in their entirety.

 

    Page 11 of 24

     

    

 

		9.	DISCLAIMER
OF WARRANTIES

 

9.1
Disclaimer. THE PATENT RIGHTS, LICENSED PRODUCTS AND ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT ARE PROVIDED ON AN
“AS IS” BASIS. UNIVERSITY MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO
ANY WARRANTY OF ACCURACY, COMPLETENESS, PERFORMANCE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY, NON-INFRINGEMENT,
ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE, OR TITLE. Specifically, and not in limitation of the foregoing,
University makes no representation or warranty (i) regarding the validity or scope of the Licensed Products, and (ii) that the
exploitation of the Patents or Patent Rights or Licensed Products will not infringe on any patents or other intellectual property
of any third party.

 

		10.	LIMITATION
OF LIABILITY

 

10.1
Limitation of Liability. UNIVERSITY WILL NOT BE LIABLE TO COMPANY, ITS AFFILIATES, SUBLICENSEES, SUCCESSORS OR ASSIGNS, OR
ANY THIRD PARTY WITH RESPECT TO ANY CLAIM: ARISING FROM COMPANY’S USE OF THE PATENT RIGHTS, LICENSED PRODUCTS OR ANY OTHER
TECHNOLOGY LICENSED UNDER THIS AGREEMENT; OR ARISING FROM THE DEVELOPMENT, TESTING, MANUFACTURE, USE OR SALE OF LICENSED PRODUCTS.
UNIVERSITY WILL NOT BE LIABLE TO COMPANY, ITS AFFILIATES, SUBLICENSEES, SUCCESSORS OR ASSIGNS, OR ANY THIRD PARTY FOR LOST PROFITS,
BUSINESS INTERRUPTION, OR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND.

 

		11.	INDEMNIFICATION

 

11.1
Indemnification. Company will defend, indemnify, and hold harmless each Indemnified Party from and against any and all Liabilities
with respect to an Indemnification Event.

 

The
term “Indemnified Party” means each of University and its trustees, officers, faculty, students, employees,
contractors, and agents.

 

The
term “Liabilities” means all damages, awards, deficiencies, settlement amounts, defaults, assessments, fines,
dues, penalties, costs, fees, liabilities, obligations, taxes, liens, losses, lost profits and expenses (including, but not limited
to, court costs, interest and reasonable fees of attorneys, accountants and other experts) that are incurred by an Indemnified
Party or awarded or otherwise required to be paid to third parties by an Indemnified Party.

 

The
term “Indemnification Event” means any Claim against one or more Indemnified Parties arising out of or resulting
from:

 

		(a)	the
development, testing, use, manufacture, promotion, sale or other disposition of any Patent Rights or Licensed Products by Company,
its Affiliates, sublicensees, assignees or vendors or third parties, including, but not limited to,

 

		(i)	any
product liability or other Claim of any kind related to use by a third party of a Licensed Product,

 

    Page 12 of 24

     

    

 

		(ii)	any
Claim by a third party that the practice of any of the Patent Rights or the design, composition, manufacture, use, sale or other
disposition of any Licensed Product infringes or violates any patent, copyright, trade secret, trademark or other intellectual
property right of such third party, and

 

		(iii)	any
Claim by a third party relating to clinical trials or studies for Licensed Products;

 

		(b)	any
material breach of the Transaction Agreements by Company or its Affiliates or sublicensees;

 

		(c)	any
Claim arising from, relating to or in connection with Company’s capital or debt raising activities, including but not limited
to its private placement memorandum, stock purchase agreements, convertible purchase arrangements and/or debt instruments, and/or
Company’s written or oral statements and/or representations made about University in all such capital or debt raising activities;
and

 

		(d)	the
enforcement of this Article 11 by any Indemnified Party.

 

The
term “Claim” means any charges, complaints, actions, suits, proceedings, hearings, investigations, claims or
demands.

 

11.2
Reimbursement of Costs. Company will pay directly all Liabilities incurred for defense or negotiation of any Claim or will
reimburse University for all documented Liabilities incident to the defense or negotiation of any Claim within thirty (30) days
after Company’s receipt of invoices for such fees, expenses and charges.

 

11.3
Control of Litigation. Company controls any litigation or potential litigation involving the defense of any Claim, including
the selection of counsel, with input from University. University reserves the right to protect its interest in defending against
any Claim by selecting its own counsel, with any attorneys’ fees and litigation expenses paid for by Company, pursuant to
Sections 11.1 and 11.2.

 

11.4
Other Provisions. Company will not settle or compromise any Claim giving rise to Liabilities in any manner that imposes any
restrictions or obligations on University or grants any rights to the Patent Rights or the Licensed Products without University’s
prior written consent. If Company fails or declines to assume the defense of any Claim within thirty (30) days after notice of
the Claim, or fails to reimburse an Indemnified Party for any Liabilities pursuant to Sections 11.1 and 11.2 within the thirty
(30) day time period set forth in Section 11.2, then University may assume the defense of such Claim for the account and at the
risk of Company, and any Liabilities related to such Claim will be conclusively deemed a liability of Company. The indemnification
rights of the Indemnified Parties under this Article 11 are in addition to all other rights that an Indemnified Party may have
at law, in equity or otherwise.

 

		12.	INSURANCE

 

12.1
Coverages. Company will procure and maintain insurance policies for the following coverages with respect to personal injury,
bodily injury and property damage arising out of Company’s performance under this Agreement: (a) during the Term, comprehensive
general liability, including broad form and contractual liability, in a minimum amount of $2,000,000 combined single limit per
occurrence and in the aggregate; (b) prior to the commencement of clinical trials involving Licensed Products, clinical trials
coverage in a minimum amount of $3,000,000 combined single limit per occurrence and in the aggregate; and (c) prior to the Sale
of the first Licensed Product, product liability coverage, in a minimum amount of $2,000,000 combined single limit per occurrence
and in the aggregate. University may review periodically the adequacy of the minimum amounts of insurance for each coverage required
by this Section 12.1, and University reserves the right to require Company to adjust the limits accordingly. The required minimum
amounts of insurance do not constitute a limitation on Company’s liability or indemnification obligations to University
under this Agreement.

 

    Page 13 of 24

     

    

 

12.2
Other Requirements. The policies of insurance required by Section 12.1 will be issued by an insurance carrier with an A.M.
Best rating of “A” or better and will name University as an additional insured with respect to Company’s performance
under this Agreement. Company will provide University with insurance certificates evidencing the required coverage within thirty
(30) days after the Effective Date and the commencement of each policy period and any renewal periods. Each certificate will provide
that the insurance carrier will notify University in writing at least thirty (30) days prior to the cancellation or material change
in coverage.

 

		13.	COMPANY’S
REPRESENTATIONS AND WARRANTIES

 

13.1
Organization, Good Standing and Qualification. Company is a corporation, duly organized, validly existing and in good standing
under the laws of the State of Nevada and has all requisite corporate power and authority to conduct on its business, to execute
and deliver this Agreement, and to consummate the transactions contemplated by this Agreement.

 

13.2
Authorization. All corporate action on the part of Company, its officers, directors and members or stockholders necessary
for the authorization, execution and delivery of this Agreement, the performance of all obligations of Company hereunder and this
Agreement, when executed and delivered by Company, will constitute valid and legally binding obligations of Company, enforceable
against Company in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance, and other laws of general application affecting enforcement of creditors’ rights generally, and as
limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

 

		14.	ADDITIONAL
PROVISIONS

 

14.1
Independent Contractors. The parties are independent contractors. Nothing contained in this Agreement is intended to create
an agency, partnership or joint venture between the parties. At no time will either party make commitments or incur any charges
or expenses for or on behalf of the other party.

 

14.2
No Discrimination. Neither University nor Company will discriminate against any employee or applicant for employment because
of race, color, sex, sexual or affectional preference, age, religion, national or ethnic origin, handicap, or veteran status.

 

    Page 14 of 24

     

    

 

14.3
Compliance with Laws. Company must comply with all prevailing laws, rules and regulations that apply to its activities or
obligations under this Agreement. For example, Company will comply with applicable United States export laws and regulations,
including, but not limited to, the export laws and regulations of the United States, and will not sell, transfer, export or re-export
any such Licensed Products or information to any persons or any third parties with regard to which there exist grounds to suspect
or believe that they are violating such laws. The transfer of certain technical data and commodities may require a license from
the applicable agency of the United States government and/or written assurances by Company that Company will not export data or
commodities to certain foreign countries without prior approval of the agency. University does not represent that no license is
required, or that, if required, the license will issue.

 

14.4
Modification, Waiver & Remedies. This Agreement may only be modified by a written amendment that is executed by an authorized
representative of each party. Any waiver must be express and in writing. No waiver by either party of a breach by the other party
will constitute a waiver of any different or succeeding breach. Unless otherwise specified, all remedies are cumulative.

 

14.5
Assignment & Hypothecation. Company may not assign this Agreement or any part of it, either directly or by merger or operation
of law, without the prior written consent of University. University will not unreasonably withhold or delay its consent, provided
that: (a) at least thirty (30) days before the proposed transaction, Company gives University written notice and such background
information as may be reasonably necessary to enable University to give an informed consent; (b) the assignee agrees in writing
to be legally bound by this Agreement and to deliver to University an updated Development Plan within forty-five (45) days after
the closing of the proposed transaction; and (c) Company provides University with a copy of assignee’s undertaking. Any permitted
assignment will not relieve Company of responsibility for performance of any obligation of Company that has accrued at the time
of the assignment. Company will not grant a security interest in the License or this Agreement during the Term. Any prohibited
assignment or security interest will be null and void.

 

14.6
Notices. Any notice or other required communication (each, a “Notice”) must be in writing, addressed to the party’s
respective Notice Address listed on the signature page, and delivered: (a) personally; (b) by certified mail, postage prepaid,
return receipt requested; (c) by recognized overnight courier service, charges prepaid; or (d) by facsimile. A Notice will be
deemed received: if delivered personally, on the date of delivery; if mailed, five (5) days after deposit in the United States
mail; if sent via courier, one (1) business day after deposit with the courier service; or if sent via facsimile, upon receipt
of confirmation of transmission provided that a confirming copy of such Notice is sent by certified mail, postage prepaid, return
receipt requested.

 

14.7
Severability & Reformation. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent
jurisdiction, then the remaining provisions of this Agreement will remain in full force and effect. Such invalid or unenforceable
provision will be automatically revised to be a valid or enforceable provision that comes as close as permitted by law to the
parties’ original intent.

 

14.8
Headings & Counterparts. The headings of the articles and sections included in this Agreement are inserted for convenience
only and are not intended to affect the meaning or interpretation of this Agreement. This Agreement may be executed in several
counterparts, all of which taken together will constitute the same instrument.

 

    Page 15 of 24

     

    

 

14.9
Governing Law. This Agreement and all amendments, exhibits, modifications, alterations, or supplements hereto, and the rights
of the parties hereunder, shall be construed under and governed by the laws of the District of Columbia, without regard to principles
of conflict of laws thereof which may require the application of the law of another jurisdiction.

 

14.10
Dispute Resolution. If a dispute arises between the parties concerning any right or duty under this Agreement, then the parties
will confer, as soon as practicable, in an attempt to resolve the dispute. If the parties are unable to resolve the dispute amicably,
then the parties will submit to the exclusive jurisdiction of, and venue in, the state and Federal courts located in the Washington,
DC with respect to all disputes arising under this Agreement.

 

14.11
Integration. This Agreement with its Appendix and Exhibits, contain the entire agreement between the parties with respect
to the Patent Rights and the License and supersede all other oral or written representations, statements, or agreements with respect
to such subject matter, including but not limited to the Term Sheet.

 

[SIGNATURES
TO FOLLOW]

 

    Page 16 of 24

     

    

 

Each
party has caused this Agreement to be executed by its duly authorized representative.

 

	THE
    GEORGE WASHINGTON UNIVERSITY	 	HOTH
    THERAPEUTICS, INC.
	 	 	 
	By: 	/s/ Mark Diaz	 	By: 	/s/ Robb Knie
	Name:  	Mark Diaz	 	Name: 	Robb Knie
	Title: 	Executive Vice President and CFO	 	Title: 	CEO
	Date:	 August 7, 2020	 	Date: 	August 3, 2020

 

Addresses:

 

	Technology
    Commercialization Office	Hoth
    Therapeutics
	The George Washington
    University	One
    Rockefeller Plaza, Suite 1039
	1922 F ST NW, 4TH
    Floor	New
    York, NY 10020
	Washington DC,
    20052	 
	Attention: TCO
    Operations Coordinator	Attention:
    Hayley Behrmann
	 	 
	Required copy to:	 
	The George Washington
    University	 
	Office of the General
    Counsel	 
	2100 Pennsylvania
    Avenue NW, Washington DC, 20052	 
	Attention: General
    Counsel	 
	202-994-6503; ogc@gwu.edu	 

 

    Page 17 of 24

     

    

 

APPENDIX
A – Key License Terms

 

		1.	License
                                         Grant.

 

		a.	Technology:

 

(1).
GW Docket [*] titled, “[*]” protected by U.S. Patent Application No. [*].

 

(2).
GW Docket [*] for “[*]”

 

		b.	Exclusivity:
                                         exclusive

 

		c.	Territory:
                                         worldwide

 

		d.	Field
                                         of Use: virus sensing and detection 

 

		2.	Diligence.

 

		a.	Diligence
                                         Minimums: each year $[*].

 

		b.	Diligence
                                         Events: listed in the table below

  

	DILIGENCE EVENT	 	COMPLETION DATE
	Commiting at least $[*] to the University in research funding for COVID-19 sensing by executing Sponsored Research Agreement	 	September 30, 2020
	Request Meeting with Government Agency to Discuss Technology	 	January 30, 2021
	Filing of FDA Application Fast Track	 	October 30, 2021
	First Sale of the Licensed Product or Licensed Service	 	January 30, 2022

 

		3.	Fees
                                         and Royalties.

 

		a.	License
                                         Initiation Fee: $[*]

 

		b.	Equity:
                                         Refer to Section 3.2 for terms related to warrants.

 

		c.	License
                                         Maintenance Fees: First year: $[*]. Second year and thereafter: $[*].

 

		d.	Milestone
                                         Payments: Per table below.

 

    Page 18 of 24

     

    

 

	MILESTONE	 	 	PAYMENT	 
	Initiation of clinical trials	 	 	$	[*]	 
	Receipt of regulatory approval for commercial sales	 	 	$	[*]	 

 

		e.	Earned
                                         Royalties: [*] % of Net Sales

 

		f.	Minimum
                                         Royalties: First 4 Quarters after first sale = $[*]. Next 8 Quarters = $[*]. Next 8 Quarters
                                         = $[*]. All Quarters thereafter = $[*].

 

		g.	Sublicense
                                         Fee: [*]%.

 

		4.	Patent
                                         Costs.

 

		a.	Past
                                         Patent Expenses: Past Patent Expenses billed to University through August 1, 2020 that
                                         have not yet been reimbursed amount to $[*]. Past Patent Expenses may also include work
                                         incurred by University prior to Effective Date, but that has not been billed to University
                                         by Effective Date.

 

		b.	By
                                         thirty (30) days after the Effective Date (the “Past Patent Expenses Reimbursement
                                         Date”) Company will reimburse University for all patent and legal expenses with
                                         respect to the Patent Rights incurred by University prior to Effective Date.

 

		c.	Ongoing
                                         patent costs to be reimbursed by Company or paid directly according to Section 7.2 of
                                         this Agreement.

 

    Page 19 of 24

     

    

 

EXHIBIT
INDEX

 

	Exhibit
    A	Patents
    and Patent Applications in Patent Rights
	 	 
	Exhibit
    B	Minimum
    Contents of Development Plan
	 	 
	Exhibit
    C	Format
of Royalty Report

	 	 
	Exhibit
    D	Invoice
    of Past Patent Costs

 

    Page 20 of 24

     

    

 

Exhibit
A

 

Patents
and Patent Applications in Patent Rights

 

	 
	 	 	 	 	 	 
	GW
    Reference	Status	Country	Application

        Number
	Title	Inventors
	[*]	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]

 

    Page 21 of 24

     

    

 

Exhibit
B

 

Minimum
Contents of Development Plan

 

The
initial Development Plan and each annual update to the Development Plan shall include, at a minimum, the following information:

 

		●	The
date of the Development Plan and the reporting period covered by the Development Plan.

 

		●	Identification
and nature of each active relationship between Company and its Affiliates, sublicensees or subcontractors in the research, development
or commercialization of Licensed Products or Patent Rights

 

		●	Significant
projects completed during the reporting period by Company or its Affiliates, sublicensees or subcontractors in the research, development
or commercialization of Licensed Products or Patent Rights.

 

		●	Significant
projects currently being performed by Company or its Affiliates, sublicensees or subcontractors in the research, development or
commercialization of Licensed Products or Patent Rights.

 

		●	Future
projects expected to be undertaken during the next reporting period by Company or its Affiliates, sublicensees or subcontractors
in the research, development or commercialization of Licensed Products or Patent Rights.

 

		●	Projected
timelines to product launch of each Licensed Product prior to first Sale.

 

		●	Projected
annual Net Sales for each Licensed Product after first Sale.

 

		●	Significant
changes to the current Development Plan since the previous Development Plan and the reasons for the changes.

 

		●	Significant
assumptions underlying the Development Plan and the future variables that may cause significant changes to the Development Plan.

 

    Page 22 of 24

     

    

 

Exhibit
C

 

Format
of Royalty Report

  

 

    Page 23 of 24

     

    

 

Exhibit
D

 

Invoice
of Past Patent Costs

 

[*]

 

 

Page 24 of
24Exhibit 10.1

 

 

 

EQUITY FINANCING AGREEMENT

 

This EQUITY FINANCING AGREEMENT (the "Agreement''), dated as
of August 7, 2020 (the "Execution Date"), is entered into by and between Cannabis Global, Inc., a Nevada corporation
with its principal executive office at 520 S Grand Ave #320, Los Angeles Ca 90071(the "Company'"), and GHS Investments
LLC, a Nevada limited liability company, with offices at 420 Jericho Turnpike, Suite 102, Jericho, NY 11753 (the "Investor").

 

RECITALS:

 

WHEREAS, the parties desire that, upon the terms and subject to the
conditions contained herein, the Investor shall invest up to Five Million Dollars ($5,000,000) (the "Commitment Amount"),
over the course of thirty six (36) months immediately following the Effective Date (the "Contract Period") to purchase
the Company's common stock, par value $0.0001 per share (the "Common Stock");

 

WHEREAS, such investments will be made in reliance upon the exemption
from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the "1933 Act"),
Rule 506 of Regulation D promulgated by the SEC under the 1933 Act, and/or upon such other exemption from the registration requirements
of the 1933 Act as may be available with respect to any or all of the investments in Common Stock to be made hereunder; and

 

WHEREAS, contemporaneously with the execution and delivery of this
Agreement, the parties hereto are executing and delivering a Registration Rights Agreement substantially in the form attached hereto
as Exhibit A (the "Registration Rights Agreement") pursuant to which the Company has agreed to provide certain registration
rights under the 1933 Act, and the rules and regulations promulgated thereunder, and applicable state securities laws.

 

NOW THEREFORE, in consideration of the foregoing recitals, which
shall be considered an integral part of this Agreement, the covenants and agreements set forth hereafter, and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the Investor hereby agree as follows:

 

SECTION I. DEFINITIONS

 

For all purposes of and under this Agreement, the following terms
shall have the respective meanings below, and such meanings shall be equally applicable to the singular and plural forms of such
defined terms.

 

    	1  

    	 

    

 

 

"1933 Act" shall have the meaning set forth in the recitals.

 

"1934 Act" shall mean the Securities Exchange Act of 1934,
as amended, or any similar federal statute, and the rules and regulations of the SEC thereunder, all as the same will then be in
effect.

 

"Affiliate" shall have the meaning set forth in Section
5.7. "Agreement" shall have the meaning set forth in the preamble. "Articles of Incorporation" shall have the
meaning set forth in Section 4.3.

 

"By-laws" shall have the meaning set forth in Section 4.3.
"Closing" shall have the meaning set forth in Section 2.4.

 

"Closing Date" shall have the meaning set forth in Section
2.4. "Commitment Note" shall have the meaning set forth in Section 2.7 "Common Stock" shall have the meaning
set forth in the recitals. "Control" or "Controls" shall have the meaning set forth in Section 5.7.

 

"Effective Date" shall mean the date the SEC declares effective
under the 1933 Act the Registration Statement covering the Securities.

 

"Environmental Laws" shall have the meaning set forth in
Section 4.13.

 

"Execution Date" shall have the meaning set forth in the
preamble.

 

"Indemnified Liabilities" shall have the meaning set forth
in Section 10.

 

"Indemnitees" shall have the meaning set forth in Section
10.

 

"Indemnitor" shall have the meaning set forth in Section
10.

 

"Ineffective Period" shall mean any period of time that
the Registration Statement or any supplemental registration statement becomes ineffective or unavailable for use for the sale or
resale, as applicable, of any or all of the Registrable Securities (as defined in the Registration Rights Agreement) for any reason
(or in the event the prospectus under either of the above is not current and deliverable) during any time period required under
the Registration Rights Agreement.

 

"Investor" shall have the meaning set forth in the preamble.

 

"Market Price" shall mean the lowest traded price of the
Common Stock during the Pricing Period.

 

    	2  

    	 

    

 

 

"Material Adverse Effect" shall have the meaning set forth
in Section 4.1.

 

"Maximum Common Stock Issuance" shall have the meaning
set forth in Section 2.5.

 

"Open Period" shall mean the period beginning on and including
the Trading Day immediately following the Effective Date and ending on the termination of the Agreement in accordance with

 

Section 8.

 

"Pricing Period" shall mean the ten (10) consecutive Trading
Days preceding the relevant Put Notice Date.

 

"Principal Market" shall mean the New York Stock Exchange,
the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the OTC Markets, whichever
is the principal market on which the Common Stock is listed.

 

"Prospectus" shall mean the prospectus, preliminary prospectus
and supplemental prospectus used in connection with the Registration Statement. "Purchase Amount" shall mean the total
amount being paid by the Investor on a particular Closing Date to purchase the Securities.

 

"Purchase Price" shall mean eighty percent (80%) of the
Market Price.

 

"Put" shall mean the Company is entitled to request equity
investments (the "Put" or "Puts") by the Investor, pursuant to which the Company will issue Common Stock to
the Investor with an aggregate Purchase Price equal to the value of the Put, subject to a price per share calculation based on
the Market Price.

 

"Put Amount" shall mean the total dollar amount requested
by the Company pursuant to an applicable Put. The timing and amounts of each Put shall be at the discretion of the Company. The
maximum dollar amount of each Put will not exceed two hundred percent (200%) of the average daily trading dollar volume for the
Common Stock during the ten (10) consecutive Trading Days preceding the Put Notice Date. No Put will be made in an amount equaling
less than ten thousand dollars ($10,000) or greater than four hundred thousand dollars ($400,000). Puts are further limited to
the Investor owning no more than 4.99% of the outstanding stock of the Company at any given time.

 

"Put Notice" shall mean a written notice sent to the Investor
by the Company stating the Put Amount in U.S. dollars that the Company intends to sell to the Investor pursuant to the terms of
the Agreement and stating the current number of Shares issued and outstanding on such date. "Put Notice Date" shall mean
the Trading Day on which the Investor receives a Put Notice.

 

    	3  

    	 

    

 

 

"Put Restriction" shall mean a minimum of ten (10) Trading
Days following a Put Notice Date. During this time, the Company shall not be entitled to deliver another Put Notice.

 

"Put Shares" shall have the meaning set forth in Section
2.4.

 

"Registered Offering Transaction Documents" shall mean
this Agreement, the Registration Rights Agreement and the Commitment Note between the Company and the Investor as of the date herewith.

 

"Registration Rights Agreement" shall have the meaning
set forth in the recitals.

 

"Registration Statement" means the registration statement
of the Company filed under the 1933 Act covering the Securities issuable hereunder.

 

"Related Party" shall have the meaning set forth in Section
5.7. "Resolution" shall have the meaning set forth in Section 7.5. "SEC" shall mean the U.S. Securities and
Exchange Commission. "SEC Documents" shall have the meaning set forth in Section 4.6.

 

"Securities" shall mean the shares of Common Stock issued
pursuant to the terms of this Agreement.

 

"Settlement Date" shall have the meaning set forth in Section
2.4.

 

"Shares" shall mean the shares of the Common Stock. "Subsidiaries"
shall have the meaning set forth in Section 4.1.

 

"Trading Day" shall mean any day on which the Principal
Market for the Common Stock is open for trading, from the hours of 9:30 am until 4:00 pm.

 

"Transaction Costs" the Company shall bear the costs of
the Registration Statement. "Waiting Period" shall have the meaning set forth in Section 2.2.

 

 

    	4  

    	 

    

 

SECTION II PURCHASE AND SALE OF COMMON STOCK

 

1. PURCHASE AND SALE OF COMMON STOCK. Subject to the terms and conditions
set forth herein, the Company shall issue and sell to the Investor, and the Investor shall purchase from the Company, up to that
number of Shares having an aggregate Purchase Price of Five Million Dollars ($5,000,000).

 

2. DELIVERY OF PUT NOTICES. Subject to the terms and conditions herein,
and from time to time during the Open Period, the Company may, in its sole discretion, deliver a Put Notice to the Investor which
states the dollar amount (designated in U.S. Dollars), which the Company intends to sell to the Investor on a Closing Date (the
"Put"). The Put Notice shall be in the form attached hereto as Exhibit C and incorporated herein by reference. The Purchase
Price of the Put shall be eighty percent (80%) percent of the Market Price. During the Open Period, the Company shall not be entitled
to submit a Put Notice until after the previous Closing has been completed. There will be a minimum of ten (10) trading days between
Put Notices. No Put will be made in an amount equaling less than ten thousand dollars ($10,000) or greater than four hundred thousand
dollars ($400,000).

 

3. CONDITIONS TO INVESTOR'S OBLIGATION TO PURCHASE SHARES. Notwithstanding
anything to the contrary in this Agreement, the Company shall not be entitled to deliver a Put Notice and the Investor shall not
be obligated to purchase any Shares at a Closing unless each of the following conditions are satisfied:

 

i. a Registration Statement shall have been declared effective and
shall remain effective and available for the resale of all the Registrable Securities (as defined in the Registration Rights Agreement)
at all times until the Closing with respect to the subject Put Notice;

 

ii. at all times during the period beginning on the related Put Notice
Date and ending on and including the related Closing Date, the Common Stock shall have been listed or quoted for trading on the
Principal Market and shall not have been suspended from trading thereon for a period of two (2) consecutive Trading Days during
the Open Period and the Company shall not have been notified of any pending or threatened proceeding or other action to suspend
the trading of the Common Stock;

 

iii. the Company has complied with its obligations and is otherwise
not in breach of or in default under, this Agreement, the Registration Rights Agreement or any other agreement executed between
the parties, which has not been cured prior to delivery of the Put Notice;

 

iv. no injunction shall have been issued and remain in force, or
action commenced by a governmental authority which has not been stayed or abandoned, prohibiting the purchase or the issuance of
the Securities; and v. the issuance of the Securities will not violate any requirements of the Principal Market.

 

If any of the events described in clauses (i) through (v) above occurs
during a Pricing Period, then the Investor shall have no obligation to purchase the Put Amount of Common Stock set forth in the
applicable Put Notice.

 

    	5  

    	 

    

 

 

4. MECHANICS OF PURCHASE OF SHARES BY INVESTOR. Subject to the satisfaction
of the conditions set forth in Sections 2.5, 7 and 8 of this Agreement, at the end of the Pricing Period, the Purchase Price shall
be established and an amount of Shares equaling one hundred percent (100%) of the Put Amount (the "Put Shares") shall
be delivered to the Investor's broker for a particular Put. The Investor shall cause the Put Amount to be placed into escrow within
one Trading Day of the Put Notice Date.

 

The Closing of a Put shall occur upon the first Trading Day following
the confirmation of receipt and approval for trading by Investor's broker of the Put Shares, whereby the Company shall have caused
the Transfer Agent to electronically transmit, prior to the applicable Closing Date, the applicable Put Shares by crediting the
account of the Investor's broker with DTC through its Deposit Withdrawal Agent Commission ("DWAC") system. The Investor
shall deliver (by informing the designated escrow agent) the Purchase Amount specified in the Put Notice, less deposit and clearing
fees, by wire transfer of immediately available funds to an account designated by the Company if the aforementioned receipt and
approval are confirmed before 9:30 AM ET or on the following Trading Day if receipt and approval by the Investor's broker is made
after 9:30 AM ET("Closing Date" or "Closing"). In addition, on or prior to such Closing Date, each of the Company
and Investor shall deliver to each other all documents, instruments and writings required to be delivered or reasonably requested
by either of them pursuant to this Agreement in order to implement and effect the transactions contemplated herein.

 

5. OVERALL LIMIT ON COMMON STOCK ISSUABLE. Notwithstanding anything
contained herein to the contrary, if during the Open Period the Company becomes listed on an exchange which limits the number of
shares of Common Stock that may be issued without shareholder approval, then the number of Shares issuable by the Company and purchasable
by the Investor, shall not exceed that number of the shares of Common Stock that may be issuable without shareholder approval (the
"Maximum Common Stock Issuance"). If such issuance of shares of Common Stock could cause a delisting on the Principal
Market then the Maximum Common Stock Issuance shall first be approved by the Company's shareholders in accordance with applicable
law and the By-laws and the Articles of Incorporation of the Company. The parties understand and agree that the Company's failure
to seek or obtain such shareholder approval shall in no way adversely affect the validity and due authorization of the issuance
and sale of Securities or the Investor's obligation in accordance with the terms and conditions hereof to purchase a number of
Shares in the aggregate up to the Maximum Common Stock Issuance, and that such approval pertains only to the applicability of the
Maximum Common Stock Issuance limitation provided in this Section 2.5.

 

    	6  

    	 

    

 

 

6. LIMITATION ON AMOUNT OF OWNERSHIP. Notwithstanding anything to
the contrary in this Agreement, in no event shall the Investor be entitled to purchase that number of Shares, which when added
to the sum of the number of shares of Common Stock beneficially owned (as such term is defined under Section 13(d) and Rule 13d-3
of the 1934 Act), by the Investor, would exceed 4.99% of the number of shares of Common Stock outstanding on the Closing Date,
as determined in accordance with Rule 13d-1(j) of the 1934 Act.

7. COMMITMENT NOTE. The Company shall issue to the Investor a fifty
thousand dollar ($50,000) promissory note to offset transaction costs ("Commitment Note"). The Commitment Note shall
be deemed earned upon the execution of this Agreement.

 

SECTION IT INVESTOR'S REPRESENTATIONS, WARRANTIES AND COVENANTS

 

The Investor represents and warrants to the Company, and covenants,
that to the best of the Investor's knowledge:

 

1. SOPHISTICATED INVESTOR. The Investor has, by reason of its business
and financial experience, such knowledge, sophistication and experience in financial and business matters and in making investment
decisions of this type that it is capable of (1) evaluating the merits and risks of an investment in the Securities and making
an informed investment decision; (II) protecting its own interest; and (III) bearing the economic risk of such investment for an
indefinite period of time.

 

2. AUTHORIZATION; ENFORCEMENT. This Agreement has been duly and validly
authorized, executed and delivered on behalf of the Investor and is a valid and binding agreement of the Investor enforceable against
the Investor in accordance with its terms, subject as to enforceability to general principles of equity and to applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement
of applicable creditors' rights and remedies.

 

3. SECTION 9 OF THE 1934 ACT. During the term of this Agreement,
the Investor will comply with the provisions of Section 9 of the 1934 Act, and the rules promulgated thereunder, with respect to
transactions involving the Common Stock.

 

    	7  

    	 

    

 

 

4. ACCREDITED INVESTOR. Investor is an "Accredited Investor'
as that term is defined in Rule 501(a) of Regulation D of the 1933 Act.

 

5. NO CONFLICTS. The execution, delivery and performance of the Documents
by the Investor and the consummation by the Investor of the transactions contemplated hereby and thereby will not result in a violation
of Partnership Agreement or other organizational documents of the Investor.

 

6. OPPORTUNITY TO DISCUSS. The Investor has received all materials
relating to the Company's business, finance and operations which it has requested. The Investor has had an opportunity to discuss
the business, management and financial affairs of the Company with the Company's management.

 

7. INVESTMENT PURPOSES. The Investor is purchasing the Securities
for its own account for investment purposes and not with a view towards distribution and agrees to resell or otherwise dispose
of the Securities solely in accordance with the registration provisions of the 1933 Act (or pursuant to an exemption from such
registration provisions).

 

8. NO REGISTRATION AS A DEALER. The Investor is not required to be
registered as a "dealer" under the 1934 Act, either as a result of its execution and performance of its obligations under
this Agreement or otherwise.

9. GOOD STANDING. The Investor is a limited liability company, duly
organized, validly existing and in good standing in the State of Nevada.

 

10. TAX LIABILITIES. The Investor understands that it is liable for
its own tax liabilities.

 

11. REGULATION M. The Investor will comply with Regulation M under
the 1934 Act, if applicable.

 

12. PROHIBITED TRADING. No short sales shall be permitted by the
Investor or its affiliates during the period commencing on the Execution Date and continuing through the termination of this Agreement.

 

    	8  

    	 

    

 

 

SECTION IV REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

Except as set forth in the Schedules attached hereto, or as disclosed
on the Company's SEC Documents, the Company represents and warrants to the Investor that:

 

1. ORGANIZATION AND QUALIFICATION. The Company is a corporation duly
organized and validly existing in good standing under the laws of the State of Nevada, and has the requisite corporate power and
authorization to own its properties and to carry on its business as now being conducted. Both the Company and the companies it
owns or controls ("Subsidiaries'') are duly qualified to do business and are in good standing in every jurisdiction in which
its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to the extent
that the failure to be so qualified or be in good standing would not have a Material Adverse Effect. As used in this Agreement,
"Material Adverse Effect" means a change, event, circumstance, effect or state of facts that has had or is reasonably
likely to have, a material adverse effect on the business, properties, assets, operations, results of operations, financial condition
or prospects of the Company and its Subsidiaries, if any, taken as a whole, or on the transactions contemplated hereby or by the
agreements and instruments to be entered into in connection herewith, or on the authority or ability of the Company to perform
its obligations under the Registered offering Transaction Documents.

 

2. AUTHORIZATION; ENFORCEMENT; COMPLIANCE WITH OTHER INSTRUMENTS.

 

i. The Company has the requisite corporate power and authority to
enter into and perform this Agreement and the Registration Rights Agreement (collectively, the "Registered Offering Transaction
Documents"), and to issue the Securities in accordance with the terms hereof and thereof.

 

ii. The execution and delivery of the Registered Offering Transaction
Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby, including without limitation
the issuance of the Securities pursuant to this Agreement, have been duly and validly authorized by the Company's Board of Directors
and no further consent or authorization is required by the Company, its Board of Directors, or its shareholders.

 

iii. The Registered Offering Transaction Documents have been duly
and validly executed and delivered by the Company.

 

iv. The Registered Offering Transaction Documents constitute the
valid and binding obligations of the Company enforceable against the Company in accordance with their

 

7

3.

 

terms, except as such enforceability may be limited by general principles
of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting
generally, the enforcement of creditors' rights and remedies.

 

    	9  

    	 

    

 

 

CAPITALIZATION. As of the date hereof, the authorized capital stock
of the Company

 

consists of: (i)290,000,000shares of the Common Stock, par value
$0.0001 per share, of which as of the date hereof 24,433,402 shares are issued and outstanding; and, (ii)10,000,000 shares of Preferred
Stock, par value $0.0001of which as of the date hereof 6,000,000Preferred Stock are issued and outstanding. All of such outstanding
shares have been, or upon issuance will be, validly issued and are fully paid and nonassessable.

 

Except as disclosed in the Company's publicly available filings with
the SEC and as will be disclosed in the Registration Statement, and based on the best information available and efforts of the
Company's management, or as otherwise set forth on Schedule 4.3:

 

i.

 

il.

 

iil.

 

iv.

 

Vi.

 

Vil.

 

Vili.

 

no shares of the Company's capital stock are subject to preemptive
rights or any other similar rights or any liens or encumbrances suffered or permitted by the Company;

 

there are no outstanding debt securities;

 

 

    	10  

    	 

    

 

there are no outstanding shares of capital stock, options, warrants,
scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible
into, any shares of capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements
by which the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company
or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries;

 

there are no agreements or arrangements under which the Company or
any of its Subsidiaries is obligated to register the sale of any of their securities under the 1933 Act (except the Registration
Rights Agreement);

 

there are no outstanding securities of the Company or any of its
Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements
by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries;

 

there are no securities or instruments containing anti-dilution or
similar provisions that will be triggered by the issuance of the Securities as described in this Agreement;

 

the Company does not have any stock appreciation rights or "phantom
stock" plans or agreements or any similar plan or agreement; and

 

there is no dispute as to the classification of any shares of the
Company's capital stock.

 

The Company has furnished to the Investor, or the Investor has had
access through

 

EDGAR to, true and correct copies of the Company's Articles of Incorporation
and all amendments thereto, as in effect on the date hereof (the "Articles of Incorporation"), and the Company's By-laws
and all amendments thereto, as in effect on the date hereof (the "By-laws"), and the terms of all securities convertible
into or exercisable for Common Stock and the material rights of the holders thereof in respect thereto.

 

 

    	11  

    	 

    

 

4. ISSUANCE OF SHARES. As of the filing of the Registration Statement
the Company will have reserved the amount of Shares included in the Registration Statement for issuance pursuant to the Registered
Offering Transaction Documents, which have been duly authorized and reserved (subject to adjustment pursuant to the Company's covenant
set forth in Section 5.5 below) pursuant to this Agreement. Upon issuance in accordance with this Agreement, the Securities will
be validly issued, fully paid for and non-assessable and free from all taxes, liens and charges with respect to the issuance thereof.
In the event the Company cannot register a sufficient number of Shares for issuance pursuant to this Agreement, the Company will
use its best efforts to authorize and reserve for issuance the number of Shares required for the Company to perform its obligations
hereunder as soon as reasonably practicable.

 

5. NO CONFLICTS. The execution, delivery and performance of the Registered
Offering Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby
will not (i) result in a violation of the Articles of Incorporation, any Certificate of Designations, Preferences and Rights of
any outstanding series of preferred stock of the Company or the By-laws; or (ii) conflict with, or constitute a material default
(or an event which with notice or lapse of time or both would become a material default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, any material agreement, contract, indenture mortgage, indebtedness or
instrument to which the Company or any of its Subsidiaries is a party, or to the Company's knowledge result in a violation of any
law, rule, regulation, order, judgment or decree (including United States federal and state securities laws and regulations and
the rules and regulations of the Principal Market or principal securities exchange or trading market on which the Common Stock
is traded or listed) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any
of its Subsidiaries is bound or affected. Neither the Company nor its Subsidiaries is in violation of any term of, or in default
under, the Articles of Incorporation, any Certificate of Designations, Preferences and Rights of any outstanding series of preferred
stock of the Company or the By-laws or their organizational charter or by-laws, respectively, or any contract, agreement, mortgage,
indebtedness, indenture, instrument, judgment, decree or order or any statute, rule or regulation applicable to the Company or
its Subsidiaries, except for possible conflicts, defaults, terminations, amendments, accelerations, cancellations and violations
that would not individually or in the aggregate have or constitute a Material Adverse Effect. The business of the Company and its
Subsidiaries is not being conducted, and shall not be conducted, in violation of any law, statute, ordinance, rule, order or regulation
of any governmental authority or agency, regulatory or self-regulatory agency, or court, except for possible violations the sanctions
for which either individually or in the aggregate would not have a Material Adverse Effect. Except as specifically contemplated
by this Agreement and as required under the 1933 Act or any securities laws of any states, to the Company's knowledge, the Company
is not required to obtain any consent, authorization, permit or order of, or make any filing or registration (except the filing
of a registration statement as outlined in the Registration Rights Agreement between the parties) with, any court, governmental
authority or agency, regulatory or self-regulatory agency or other third party in order for it to execute, deliver or perform any
of its obligations under, or contemplated by, the Registered Offering Transaction Documents in accordance with the terms hereof
or thereof. All consents, authorizations, permits, orders, filings and registrations which the Company is required to obtain pursuant
to the preceding sentence have been obtained or effected on or prior to the date hereof and are in full force and effect as of
the date hereof. The Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the
foregoing. The Company is not, and will not be, in violation of the listing requirements of the Principal Market as in effect on
the date hereof and on each of the Closing Dates and is not aware of any facts which would reasonably lead to delisting of the
Common Stock by the Principal Market in the foreseeable future.

 

    	12  

    	 

    

 

 

6. SEC DOCUMENTS; FINANCIAL STATEMENTS. As of the date hereof, the
Company has filed all reports, schedules, forms, statements and other documents required to be filed by it

9 with the SEC pursuant to the reporting requirements of the 1934
Act (all of the foregoing filed prior to the date hereof and all exhibits included therein and financial statements and schedules
thereto and documents incorporated by reference therein, and amendments thereto, being hereinafter referred to as the "SEC
Documents"). The Company has delivered to the Investor or its representatives, or they have had access through EDGAR to, true
and complete copies of the SEC Documents. As of their respective filing dates, the SEC Documents complied in all material respects
with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents,
and none of the SEC Documents, at the time they were filed with the SEC or the time they were amended, if amended, contained any
untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading. As of their respective dates, the
financial statements of the Company included in the SEC Documents complied as to form in all material respects with applicable
accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial statements have
been prepared in accordance with generally accepted accounting principles, by a firm that is a member of the Public Companies Accounting
Oversight Board ("PCAOB") consistently applied, during the periods involved (except (i) as may be otherwise indicated
in such financial statements or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may
exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial position
of the Company as of the dates thereof and the results of its operations and cash flows for the periods then ended (subject, in
the case of unaudited statements, to normal year-end audit adjustments). No other written information provided by or on behalf
of the Company to the Investor which is not included in the SEC Documents, including, without limitation, information referred
to in Section

 

    	13  

    	 

    

 

4.3 of this Agreement, contains any untrue statement of a material
fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstance under which
they are or were made, not misleading. Neither the Company nor any of its Subsidiaries or any of their officers, directors, employees
or agents have provided the Investor with any material, nonpublic information which was not publicly disclosed prior to the date
hereof and any material, nonpublic information provided to the Investor by the Company or its Subsidiaries or any of their officers,
directors, employees or agents prior to any Closing Date shall be publicly disclosed by the Company prior to such Closing Date.

 

7. ABSENCE OF CERTAIN CHANGES. Except as otherwise set forth in the
SEC Documents, the Company does not intend to change the business operations of the Company in any material way. The Company has
not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any bankruptcy law nor does
the Company or its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy
proceedings.

 

8. ABSENCE OF LITIGATION AND/OR REGULATORY PROCEEDINGS. Except as
set forth in the SEC Documents, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board,
government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of Company or any
of its Subsidiaries, threatened against or affecting the Company, the Common Stock or any of the Company's Subsidiaries or any
of the Company's or the Company's Subsidiaries' officers or directors in their capacities as such, in which an adverse decision
could have a Material Adverse Effect.

 

9. ACKNOWLEDGMENT REGARDING INVESTOR'S P HASE OF SHARES. The Company
acknowledges and agrees that the Investor is acting solely in the capacity of an arm's length investor with respect to the Registered
Offering Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges that the
Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar

 

10 capacity) with respect to the Registered Offering Transaction
Documents and the transactions contemplated hereby and thereby and any advice given by the Investor or any of its respective representatives
or agents in connection with the Registered Offering Transaction Documents and the transactions contemplated hereby and thereby
is merely incidental to the Investor's purchase of the Securities, and is not being relied on by the Company. The Company further
represents to the Investor that the Company's decision to enter into the Registered Offering Transaction Documents has been based
solely on the independent evaluation by the Company and its representatives.

 

    	14  

    	 

    

 

 

10. NO UNDISCLOSED EVENTS, LIABILITIES, DEVELOPMENTS OR CIRCUMSTANCES.
Except as set forth in the SEC Documents, as of the date hereof, no event, liability, development or circumstance has occurred
or exists, or to the Company's knowledge is contemplated to occur, with respect to the Company or its Subsidiaries or their respective
business, properties, assets, prospects, operations or financial condition, that would be required to be disclosed by the Company
under applicable securities laws on a registration statement filed with the SEC relating to an issuance and sale by the Company
of its Common Stock and which has not been publicly announced.

 

11. EMPLOYEE RELATIONS. Neither the Company nor any of its Subsidiaries
is involved in any union labor dispute nor, to the knowledge of the Company or any of its Subsidiaries, is any such dispute threatened.
Neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries
believe that relations with their employees are good. No executive officer (as defined in Rule 501(f) of the 1933 Act) has notified
the Company that such officer intends to leave the Company's employ or otherwise terminate such officer's employment with the Company.

 

12. INTELLECTUAL PROPERTY RIGHTS. The Company and its Subsidiaries
own or possess adequate rights or licenses to use all trademarks, trade names, service marks, service mark registrations, service
names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and rights
necessary to conduct their respective businesses as now conducted. Except as set forth in the SEC Documents, none of the Company's
trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions,
licenses, approvals, government authorizations, trade secrets or other intellectual property rights necessary to conduct its business
as now or as proposed to be conducted have expired or terminated, or are expected to expire or terminate within two (2) years from
the date of this Agreement. The Company and its Subsidiaries do not have any knowledge of any infringement by the Company or its
Subsidiaries of trademark, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names, service
marks, service mark registrations, trade secret or other similar rights of others, or of any such development of similar or identical
trade secrets or technical information by others and, except as set forth in the SEC Documents, there is no claim, action or proceeding
being made or brought against, or to the Company's knowledge, being threatened against, the Company or its Subsidiaries regarding
trademark, trade name, patents, patent rights, invention, copyright, license, service names, service marks, service mark registrations,
trade secret or other infringement; and the Company and its Subsidiaries are unaware of any facts or circumstances which might
give rise to any of the foregoing. The Company and its Subsidiaries have taken commercially reasonable security measures to protect
the secrecy, confidentiality and value of all of their intellectual properties.

 

    	15  

    	 

    

 

 

13. ENVIRONMENTAL LAWS. The Company and its Subsidiaries (i) are,
to the knowledge of the management and directors of the Company and its Subsidiaries, in compliance with any and all applicable
foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or
hazardous or toxic substances or wastes,

11 pollutants or contaminants ("Environmental Laws"); (ii)
have, to the knowledge of the management and directors of the Company, received all permits, licenses or other approvals required
of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance, to the knowledge
of the management and directors of the Company, with all terms and conditions of any such permit, license or approval where, in
each of the three (3) foregoing cases, the failure to so comply would have, individually or in the aggregate, a Material Adverse
Effect.

 

14. TITLE. The Company and its Subsidiaries have good and marketable
title to all personal property owned by them which is material to the business of the Company and its Subsidiaries, in each case
free and clear of all liens, encumbrances and defects except such as are described in the SEC Documents or such as do not materially
affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company
or any of its Subsidiaries. Any real property and facilities held under lease by the Company or any of its Subsidiaries are held
by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use
made and proposed to be made of such property and buildings by the Company and its Subsidiaries.

 

15. INSURANCE. Each of the Company's Subsidiaries are insured by
insurers of recognized financial responsibility against such losses and risks and in such amounts as management of the Company
reasonably believes to be prudent and customary in the businesses in which the Company and its Subsidiaries are engaged. Neither
the Company nor any of its Subsidiaries has been refused any insurance coverage sought or applied for and neither the Company nor
its Subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not
have a Material Adverse Effect.

 

    	16  

    	 

    

 

 

16. REGULATORY PERMITS. The Company and its Subsidiaries have in
full force and effect all certificates, approvals, authorizations and permits from the appropriate federal, state, local or foreign
regulatory authorities and comparable foreign regulatory agencies, necessary to own, lease or operate their respective properties
and assets and conduct their respective businesses, and neither the Company nor any such Subsidiary has received any notice of
proceedings relating to the revocation or modification of any such certificate, approval, authorization or permit, except for such
certificates, approvals, authorizations or permits which if not obtained, or such revocations or modifications which, would not
have a Material Adverse Effect.

 

17. INTERNAL ACCOUNTING CONTROLS. Except as otherwise set forth in
the SEC Documents, the Company and each of its Subsidiaries maintain a system of internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance with management's general or specific authorizations; (ii)
transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting
principles by a firm with membership to the PCAOB and to maintain asset accountability; (iii) access to assets is permitted only
in accordance with management's general or specific authorization; and (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company's
management has determined that the Company's internal accounting controls were not effective as of the date of this Agreement as
further described in the SEC Documents.

 

18. NO MATERIALLY ADVERSE CONTRACTS, ETC. Neither the Company nor
any of its Subsidiaries is subject to any charter, corporate or other legal restriction, or any judgment, decree, order, rule
or regulation which in the judgment of the Company's officers has or is expected in the 12 future to have a Material Adverse Effect.
Neither the Company nor any of its Subsidiaries is a party to any contract or agreement which in the judgment of the Company's
officers has or is expected to have a Material Adverse Effect.

 

19. TAX STATUS. The Company and each of its Subsidiaries has made
or filed all United States federal and state income and all other tax returns, reports and declarations required by any jurisdiction
to which it is subject (unless and only to the extent that the Company and each of its Subsidiaries has set aside on its books
provisions reasonably adequate for the payment of all unpaid and unreported taxes) and has paid all taxes and other governmental
assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except
those being contested in good faith and has set aside on its books provision reasonably adequate for the payment of all taxes for
periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any
such claim.

 

 

    	17  

    	 

    

 

20. CERTAIN TRANSACTIONS. Except as set forth in the SEC Documents
filed at least ten (10) days prior to the date hereof and except for arm's length transactions pursuant to which the Company makes
payments in the ordinary course of business upon terms no less favorable than the Company could obtain from disinterested third
parties, none of the officers, directors, or employees of the Company is presently a party to any transaction with the Company
or any of its Subsidiaries (other than for services as employees, officers and directors), including any contract, agreement or
other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from,
or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any corporation,
partnership, trust or other entity in which any officer, director, or any such employee has a substantial interest or is an officer,
director, trustee or partner, such that disclosure would be required in the SEC Documents..

 

21. DILUTIVE EFFECT. The Company understands and acknowledges that
the number of shares of Common Stock issuable upon purchases pursuant to this Agreement will increase in certain circumstances
including, but not necessarily limited to, the circumstance wherein the trading price of the Common Stock declines during the period
between the Effective Date and the end of the Open Period. The Company's executive officers and directors have studied and fully
understand the nature of the transactions contemplated by this Agreement and recognize that they have a potential dilutive effect
on the shareholders of the Company. The Board of Directors of the Company has concluded, in its good faith business judgment, and
with full understanding of the implications, that such issuance is in the best interests of the Company. The Company specifically
acknowledges that, subject to such limitations as are expressly set forth in the Registered Offering Transaction Documents, its
obligation to issue shares of Common Stock upon purchases pursuant to this Agreement is absolute and unconditional regardless of
the dilutive effect that such issuance may have on the ownership interests of other shareholders of the Company.

 

22. NO GENERAL SOLICITATION. Neither the Company, nor any of its
affiliates, nor any person acting on its behalf, has engaged in any form of general solicitation or general advertising (within
the meaning of Regulation D) in connection with the offer or sale of the Common Stock to be offered as set forth in this Agreement.

 

    	18  

    	 

    

 

23. NO BROKERS, FINDERS OR FINANCIAL ADVISORY FEES OR COMMISSIONS.
_No brokers, finders or financial advisory fees or commissions will be payable by the Company, its agents or Subsidiaries, with
respect to the transactions contemplated by this Agreement.

13

 

24. EXCLUSIVITY. The Company shall not pursue a similar equity financing
transaction as envisioned hereunder (the "Equity Financing") with any other party unless and until good faith negotiations
have terminated between the Investor and the Company or until such time as the Registration Statement has been declared effective
by the SEC.

 

SECTION V COVENANTS OF THE COMPANY

 

1. BEST EFFORTS. The Company shall use all commercially reasonable
efforts to timely satisfy each of the conditions set forth in Section 7 of this Agreement.

 

2. REPORTING STATUS. Until one of the following occurs, the Company
shall file all reports required to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate its status,
or take an action or fail to take any action, which would terminate its status as a reporting company under the 1934 Act: (i) this
Agreement terminates pursuant to Section 8 and the Investor has the right to sell all of the Securities without restrictions pursuant
to Rule 144 promulgated under the 1933 Act, or such other exemption, or (ii) the date on which the Investor has sold all the Securities
and this Agreement has been terminated pursuant to Section 8.

 

3. USE OF PROCEEDS. The Company will use the proceeds from the sale
of the Put Shares (excluding amounts paid by the Company for fees as set forth in the Registered Offering Transaction Documents)
for general corporate and working capital purposes and acquisitions or assets, businesses or operations or for other purposes that
the Board of Directors, in good faith, deem to be in the best interest of the Company.

 

4. FINANCIAL INFORMATION. During the Open Period, the Company agrees
to make available to the Investor via EDGAR or other electronic means the following documents and information on the forms set
forth: (i) within five (5) Trading Days after the filing thereof with the SEC, a copy of its Annual Reports on Form 10-K, its Quarterly
Reports on Form 10-Q, any Current Reports on Form 8-K and any Registration Statements or amendments filed pursuant to the 1933
Act; (11) copies of any notices and other information made available or given to the shareholders of the Company generally, contemporaneously
with the making available or giving thereof to the shareholders; and (iii) within two (2) calendar days of filing or delivery thereof,
copies of all documents filed with, and all correspondence sent to, the Principal Market, any securities exchange or market, or
the Financial Industry Regulatory Association, unless such information is material nonpublic information.

 

    	19  

    	 

    

 

 

5. RESERVATION OF SHARES. The Company shall take all action necessary
to at all times have authorized, and reserved the amount of Shares included in the Company's registration statement for issuance
pursuant to the Registered Offering Transaction Documents. In the event that the Company determines that it does not have a sufficient
number of authorized shares of Common Stock to reserve and keep available for issuance as described in this Section 5.5, the Company
shall use all commercially reasonable efforts to increase the number of authorized shares of Common Stock by seeking shareholder
approval for the authorization of such additional shares.

 

6. LISTING. The Company shall promptly secure and maintain the listing
of all of the Registrable Securities (as defined in the Registration Rights Agreement) on the Principal Market and each other
national securities exchange and automated quotation system, if any, upon which shares of Common Stock are then listed (subject
to official notice of issuance) and shall maintain, such listing of all Registrable Securities from time to time issuable under
the terms of the Registered Offering Transaction Documents. Neither the Company nor any of its Subsidiaries shall take any action
which would be reasonably expected to result in the delisting or suspension 14 of the Common Stock on the Principal Market (excluding
suspensions of not more than one (1) Trading Day resulting from business announcements by the Company). The Company shall promptly
provide to the Investor copies of any notices it receives from the Principal Market regarding the continued eligibility of the
Common Stock for listing on such automated quotation system or securities exchange. The Company shall pay all fees and expenses
in connection with satisfying its obligations under this Section 5.6.

 

    	20  

    	 

    

 

 

7. TRANSACTIONS WITH AFFILIATES. The Company shall not, and shall
cause each of its Subsidiaries not to, enter into, amend, modify or supplement, or permit any Subsidiary to enter into, amend,
modify or supplement, any agreement, transaction, commitment or arrangement with any of its or any Subsidiary's officers, directors,
persons who were officers or directors at any time during the previous two (2) years, shareholders who beneficially own 5% or more
of the Common Stock, or Affiliates or with any individual related by blood, marriage or adoption to any such individual or with
any entity in which any such entity or individual owns a 5% or more beneficial interest (each a "Related Party''), except
for (i) customary employment arrangements and benefit programs on reasonable terms, (ii) any agreement, transaction, commitment
or arrangement on an arms-length basis on terms no less favorable than terms which would have been obtainable from a disinterested
third party other than such Related Party, or (iii) any agreement, transaction, commitment or arrangement which is approved by
a majority of the disinterested directors of the Company. For purposes hereof, any director who is also an officer of the Company
or any Subsidiary of the Company shall not be a disinterested director with respect to any such agreement, transaction, commitment
or arrangement. "Affiliate" for purposes hereof means, with respect to any person or entity, another person or entity
that, directly or indirectly, (i) has a 5% or more equity interest in that person or entity, (ii) has 5% or more common ownership
with that person or entity, (iii) controls that person or entity, or (iv) is under common control with that person or entity. "Control"
or "Controls" for purposes hereof means that a person or entity has the power, directly or indirectly, to conduct or
govern the policies of another person or entity.

 

8. FILING OF FORM 8-K. On or before the date which is four (4) Trading
Days after the Execution Date, the Company shall file a Current Report on Form 8-K with the SEC describing the terms of the transaction
contemplated by the Registered Offering Transaction Documents in the form required by the 1934 Act, if such filing is required.

 

9. CORPORATE EXISTENCE. The Company shall use all commercially reasonable
efforts to preserve and continue the corporate existence of the Company.

 

    	21  

    	 

    

 

 

10. NOTICE OF CERTAIN EVENTS AFFECTING REGISTRATION; SUSPENSION OF
RIGHT TO MAKE A PUT. The Company shall promptly notify the Investor upon the occurrence of any of the following events in respect
of a Registration Statement or related prospectus in respect of an offering of the Securities: (i) receipt of any request for additional
information by the SEC or any other federal or state governmental authority during the period of effectiveness of the Registration
Statement for amendments or supplements to the Registration Statement or related prospectus; (ii) the issuance by the SEC or any
other federal or state governmental authority of any stop order suspending the effectiveness of any Registration Statement or the
initiation of any proceedings for that purpose; (iii) receipt of any notification with respect to the suspension of the qualification
or exemption from qualification of any of the Securities for sale in any jurisdiction or the initiation or notice of any proceeding
for such purpose; (iv) the happening of any event that makes any statement made in such Registration Statement or related prospectus
or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires
the making of any changes in the Registration Statement, related prospectus or documents so that, in the case of a Registration
Statement, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading, and that in the case of the related prospectus, it will

 

15 not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading; and (v) the Company's reasonable determination that a post-effective amendment or supplement
to the Registration Statement would be appropriate, and the Company shall promptly make available to Investor any such supplement
or amendment to the related prospectus. The Company shall not deliver to Investor any Put Notice during the continuation of any
of the foregoing events in this Section 5.10.

 

11. TRANSFER AGENT. The Company shall deliver instructions to its
transfer agent to issue Shares to the Investor that are issued to the Investor pursuant to the Equity Financing and transactions
contemplated herein.

 

12. ACKNOWLEDGEMENT OF TERMS. The Company hereby represents and warrants
to the Investor that: (i) it is voluntarily entering into this Agreement of its own free will, (ii) it is not entering this Agreement
under economic duress, (iii) the terms of this Agreement are reasonable and fair to the Company, and (iv) the Company has had independent
legal counsel of its own choosing review this Agreement, advise the Company with respect to this Agreement, and represent the Company
in connection with this Agreement.

 

SECTION VI CONDITIONS OF THE COMPANY'S OBLIGATION TO SELL

 

The obligation hereunder of the Company to issue and sell the Securities
to the Investor is further subject to the satisfaction, at or before each Closing Date, of each of the following conditions set
forth below. These conditions are for the Company's sole benefit and may be waived by the Company at any time in its sole discretion.

 

1. The Investor shall have executed this Agreement and the Registration
Rights Agreement and delivered the same to the Company.

 

2. The Investor shall have delivered to the Company the Purchase
Price for the Securities being purchased by the Investor.

 

3. No statute, rule, regulation, executive order, decree, ruling
or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction
which prohibits the consummation of any of the transactions contemplated by this Agreement.

 

    	22  

    	 

    

 

 

SECTION VII FURTHER CONDITIONS OF THE INVESTOR'S OBLIGATION TO PURCHASE

 

The obligation of the Investor hereunder to purchase Securities is
subject to the satisfaction, on or before each Closing Date, of each of the following conditions set forth below.

 

1. The Company shall have executed the Registered Offering Transaction
Documents and delivered the same to the Investor.

 

2. The representations and warranties of the Company shall be true
and correct as of the date when made and as of the applicable Closing Date as though made at that time and the Company shall have
performed, satisfied and complied with the covenants, agreements and conditions required by the Registered Offering Transaction
Documents to be performed, satisfied or complied with by the Company on or before such Closing Date. The Investor may request an
update as of such Closing Date regarding the representation contained in Section 4.3.

 

16

3. The Company shall have executed and delivered to the Investor
via DWAC the Securities (in such denominations as the Investor shall request) being purchased by the Investor at such Closing.

 

4. The Board of Directors of the Company shall have adopted resolutions
consistent with Section 4.2(ii) (the "Resolutions") and such Resolutions shall not have been amended or rescinded prior
to such Closing Date.

 

5. No statute, rule, regulation, executive order, decree, ruling
or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction
which prohibits the consummation of any of the transactions contemplated by this Agreement.

 

6. Within thirty (30) calendar days after the Agreement is executed,
the Company agrees to use its best efforts to file with the SEC the Registration Statement covering the shares of stock underlying
the Equity Financing contemplated herein. Such Registration Statement shall conform to the requirements of the rules and regulations
of the SEC, and be subject to the reasonable approval of the Investor. The Company will take any and all steps necessary to have
its Registration Statement declared effective by the SEC within 30 calendar days but no more than 90 calendar days after the Company
has filed its Registration Statement. The Registration Statement shall be effective on each Closing Date and no stop order suspending
the effectiveness of the Registration statement shall be in effect or to the Company's knowledge shall be pending or threatened.
Furthermore, on each Closing Date (I) neither the Company nor the Investor shall have received notice that the SEC has issued or
intends to issue a stop order with respect to such Registration Statement or that the SEC otherwise has suspended or withdrawn
the effectiveness of such Registration Statement, either temporarily or permanently, or intends or has threatened to do so (unless
the SEC's concerns have been addressed), and (II) no other suspension of the use or withdrawal of the effectiveness of such Registration
Statement or related prospectus shall exist.

 

    	23  

    	 

    

 

 

7. At the time of each Closing, the Registration Statement (including
information or documents incorporated by reference therein) and any amendments or supplements thereto shall not contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein not misleading or which would require public disclosure or an update supplement to the prospectus.

 

8. If applicable, the shareholders of the Company shall have approved
the issuance of any Shares in excess of the Maximum Common Stock Issuance in accordance with Section 2.5 or the Company shall have
obtained appropriate approval pursuant to the requirements of applicable state and federal laws and the Company's Articles of Incorporation
and By-laws.

 

9. The conditions to such Closing set forth in Section 2.3 shall
have been satisfied on or before such Closing Date.

 

10. The Company shall have certified to the Investor the number of
Shares of Common Stock outstanding when a Put Notice is given to the Investor. The Company's delivery of a Put Notice

 

to the Investor constitutes the Company's certification of the existence
of the necessary number of shares of Common Stock reserved for issuance.

 

SECTION VHI TERMINATION

 

This Agreement shall terminate upon any of the following events:

 

17

1. when the Investor has purchased an aggregate of Five Million Dollars
($5,000,000) in the Common Stock of the Company pursuant to this Agreement; or

 

 

    	24  

    	 

    

 

2. thirty-six (36) months from the date of this Agreement's execution
have elapsed.

 

Any and all shares, or penalties, if any, due under this Agreement
shall be immediately payable and due upon termination of this Agreement.

 

SECTION IX SUSPENSION

 

This Agreement shall be suspended upon any of the following events,
and shall remain suspended until such event is rectified:

 

i. The trading of the Common Stock is suspended by the SEC, the Principal
Market or FINRA for a period of two (2) consecutive Trading Days during the Open Period; or

 

ii. The Common Stock ceases to be quoted, listed or traded on the
Principal Market or the Registration Statement is no longer effective (except as permitted hereunder). Immediately upon the occurrence
of one of the above-described events, the Company shall send written notice of such event to the Investor.

 

SECTION X INDEMNIFICATION

 

In consideration of the parties mutual obligations set forth in the
Transaction Documents, the Company ( the "Indemnitor") shall defend, protect, indemnify and hold harmless the Investor
and all of the investor's shareholders, officers, directors, employees, counsel, and direct or indirect investors and any of the
foregoing person's agents or other representatives (including, without limitation, those retained in connection with the transactions
contemplated by this Agreement) (collectively, the "Indemnitees'') from and against any and all actions, causes of action,
suits, claims, losses, costs, penalties, fees, liabilities and damages, and reasonable expenses in connection therewith (irrespective
of whether any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable
attorneys' fees and disbursements (the "Indemnified Liabilities"), incurred by any Indemnitee as a result of, or arising
out of, or relating to (I) any misrepresentation or breach of any representation or warranty made by the Indemnitor or any other
certificate, instrument or document contemplated hereby or thereby; (II) any breach of any covenant, agreement or obligation of
the Indemnitor contained in the Registered Offering Transaction Documents or any other certificate, instrument or document contemplated
hereby or thereby; or (III) any cause of action, suit or claim brought or made against such Indemnitee by a third party and arising
out of or resulting from the execution, delivery, performance or enforcement of the Registered Offering Transaction Documents or
any other certificate, instrument or document contemplated hereby or thereby, except insofar as any such misrepresentation, breach
or any untrue statement, alleged untrue statement, omission or alleged omission is made in reliance upon and in conformity with
information furnished to Indemnitor which is specifically intended for use in the preparation of any such Registration Statement,
preliminary prospectus, prospectus or amendments to the prospectus. To the extent that the foregoing undertaking by the Indemnitor
may be unenforceable for any reason, the Indemnitor shall make the maximum contribution to the payment and satisfaction of each
of the Indemnified Liabilities which is permissible under applicable law. The indemnity provisions contained herein shall be in
addition to any cause of action or similar rights Indemnitor may have, and any liabilities the Indemnitor or the Indemnitees may
be subject to.

 

    	25  

    	 

    

 

 

18 SECTION XI GOVERNING LAW; DISPUTES SUBMITTED TO ARBITRATION.

 

1. LAW GOVERNING THIS AGREEMENT. This Agreement shall be governed
by and construed in accordance with the laws of the State of Nevada without regard to principles of conflicts of laws. Any action
brought by either party against the other concerning the transactions contemplated by this Agreement shall be brought only in the
state or federal courts located in New York City, New York State. The parties to this Agreement hereby irrevocably waive any objection
to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or
venue or based upon forum non conveniens. The parties executing this Agreement and other agreements referred to herein or delivered
in connection herewith on behalf of the Company agree to submit to the in personam jurisdiction of such courts and hereby irrevocably
waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees and
costs. In the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid or
unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it
may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove
invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.
Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding
in connection with this Agreement or any other Transaction Documents by mailing a copy thereof via registered or certified mail
or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

 

    	26  

    	 

    

 

 

2. LEGAL FEES; AND MISCELLANEOUS FEES. Except as otherwise set forth
in the Registered Offering Transaction Documents (including but not limited to Section V of the Registration Rights Agreement),
each party shall pay the fees and expenses of its advisers, counsel, the accountants and other experts, if any, and all other expenses
incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. Any attorneys'
fees and expenses incurred by either the Company or the Investor in connection with the preparation, negotiation, execution and
delivery of any amendments to this Agreement or relating to the enforcement of the rights of any party, after the occurrence of
any breach of the terms of this Agreement by another party or any default by another party in respect of the transactions contemplated
hereunder, shall be paid on demand by the party which breached the Agreement and/or defaulted, as the case may be. The Company
shall pay all stamp and other taxes and duties levied in connection with the issuance of any Securities.

 

3. COUNTERPARTS. This Agreement may be executed in any number of
counterparts and by the different signatories hereto on separate counterparts, each of which, when so executed, shall be deemed
an original, but all such counterparts shall constitute but one and the same instrument. This Agreement may be executed by facsimile
transmission, PDF, electronic signature or other similar electronic means with the same force and effect as if such signature page
were an original thereof.

 

4. HEADINGS; SINGULAR/PLURAL. The headings of this Agreement are
for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement. Whenever required by
the context of this Agreement, the singular shall include the plural and masculine shall include the feminine.

 

19

5. SEVERABILITY. If any provision of this Agreement shall be invalid
or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the
remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other
jurisdiction.

 

6. ENTIRE AGREEMENT; AMENDMENTS. This Agreement is the FINAL AGREEMENT
between the Company and the Investor with respect to the terms and conditions set forth herein, and, the terms of this Agreement
may not be contradicted by evidence of prior, contemporaneous, or subsequent oral agreements of the Parties. No provision of this
Agreement may be amended other than by an instrument in writing signed by the Company and the Investor, and no provision hereof
may be waived other than by an instrument in writing signed by the party against whom enforcement is sought. The execution and
delivery of the Registered Offering Transaction Documents shall not alter the force and effect of any other agreements between
the Parties, and the obligations under those agreements.

 

    	27  

    	 

    

 

 

7. NOTICES. Any notices or other communications required or permitted
to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered (I) upon receipt, when
delivered personally; (II) upon receipt, when sent by email; or (III) one (1) day after deposit with a nationally recognized overnight
delivery service, in each case properly addressed to the party to receive the same. The addresses for such communications shall
be:

 

If to the Company: Attn: Cannabis Global Inc 520 S Grand Ave #320
Los Angeles Ca 90071

 

With a copy to

 

(which copy shall not

 

constitute notice):

 

If to the Investor: GHS Investments, LLC 420 Jericho Turnpike, Suite
102

 

Jericho, NY 11753

 

Each party shall provide five (5) days prior written notice to the
other party of any change in address.

 

8. NO ASSIGNMENT. This Agreement may not be assigned.

 

9. NO THIRD PARTY BENEFICIARIES. This Agreement is intended for the
benefit of the parties hereto and is not for the benefit of, nor may any provision hereof be enforced by, any other

 

20 person, except that the Company acknowledges that the rights of
the Investor may be enforced by its general partner.

 

10. SURVIVAL. The representations and warranties of the Company and
the Investor contained in Sections 3 and 4, the agreements and covenants set forth in Sections 5 and 6, and the indemnification
provisions set forth in Section 10, shall survive each of the Closings and the termination of this Agreement.

 

    	28  

    	 

    

 

 

11. PUBLICITY. The Investor acknowledges that this Agreement and
all or part of the Registered Offering Transaction Documents may be deemed to be "material contracts" as that term is
defined by Item 601(b)(10) of Regulation S-K, and that the Company may therefore be required to file such documents as exhibits
to reports or registration statements filed under the 1933 Act or the 1934 Act. The Investor further agrees that the status of
such documents and materials as material contracts shall be determined solely by the Company, in consultation with its counsel.

 

12. FURTHER ASSURANCES. Each party shall do and perform, or cause
to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates,
instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes
of this Agreement and the consummation of the transactions contemplated hereby.

13. PLACEMENT AGENT. If so required, the Company agrees to pay a
registered broker dealer, to act as placement agent. The Investor shall have no obligation with respect to any fees or with respect
to any claims made by or on behalf of other persons or entities for fees of a type contemplated in this Section that may be due
in connection with the transactions contemplated by the Registered Offering Transaction Documents. The Company shall indemnify
and hold harmless the Investor, their employees, officers, directors, agents, and partners, and their respective affiliates, from
and against all claims, losses, damages, costs (including the costs of preparation and attorney's fees) and expenses incurred in
respect of any such claimed or existing fees, as such fees and expenses are incurred.

 

14. NO STRICT CONSTRUCTION. The language used in this Agreement will
be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be
applied against any party, as the parties mutually agree that each has had a full and fair opportunity to review this Agreement
and seek the advice of counsel on it.

15. REMEDIES. The Investor shall have all rights and remedies set
forth in this Agreement and the Registration Rights Agreement and all rights and remedies which such holders have been granted
at any time under any other agreement or contract and all of the rights which the Investor has by law. Any person having any rights
under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting a bond or other security),
to recover damages by reason of any default or breach of any provision of this Agreement, including the recovery of reasonable
attorneys fees and costs, and to exercise all other rights granted by law.

 

    	29  

    	 

    

 

 

16. PAYMENT SET ASIDE. To the extent that the Company makes a payment
or payments to the Investor hereunder or under the Registration Rights Agreement or the Investor enforces or exercises its rights
hereunder or thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently
invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded,
repaid or otherwise restored to the Company, a trustee, receiver or any other person under any law (including, without limitation,
any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration
the obligation or part thereof originally

 

21 intended to be satisfied shall be revived and continued in full
force and effect as if such payment had not been made or such enforcement or setoff had not occurred.

 

17. PRICING OF COMMON STOCK. For purposes of this Agreement, the
price of the Common Stock shall be as reported by Quotestream Media.

 

SECTION XII NON-DISCLOSURE OF NON-PUBLIC INFORMATION

 

The Company shall not disclose non-public information to the Investor,
its advisors, or its representatives.

 

Nothing herein shall require the Company to disclose non-public information
to the Investor or its advisors or representatives, and the Company represents that it does not disseminate non-public information
to any investors who purchase stock in the Company in a public offering, to money managers or to securities analysts, provided,
however, that notwithstanding anything herein to the contrary, the Company will, as hereinabove provided, immediately notify the
advisors and representatives of the Investor and, if any, underwriters, of any event or the existence of any circumstance (without
any obligation to disclose the specific event or circumstance) of which it becomes aware, constituting non- public information
(whether or not requested of the Company specifically or generally during the course of due diligence by such persons or entities),
which, if not disclosed in the prospectus included in the Registration Statement would cause such prospectus to include a material
misstatement or to omit a material fact required to be stated therein in order to make the statements, therein, in light of the
circumstances in which they were made, not misleading. Nothing contained in this Section 12 shall be construed to mean that such
persons or entities other than the Investor (without the written consent of the Investor prior to disclosure of such information)
may not obtain non-public information in the course of conducting due diligence in accordance with the terms of this Agreement
and nothing herein shall prevent any such persons or entities from notifying the Company of their opinion that based on such due
diligence by such persons or entities, that the Registration Statement contains an untrue statement of material fact or omits a
material fact required to be stated in the Registration Statement or necessary to make the statements contained therein, in light
of the circumstances in which they were made, not misleading.

 

    	30  

    	 

    

 

 

SECTION XII ACKNOWLEDGEMENTS OF THE PARTIES

 

Notwithstanding anything in this Agreement to the contrary, the parties
hereto hereby acknowledge and agree to the following: (i) the Investor makes no representations or covenants that it will not engage
in trading in the securities of the Company, other than as provided in Section 3.12 of this Agreement; (ii) the Company shall,
by 8:30 a.m. EST on the fourth Trading Day following the date hereof, file a current report on Form 8-K disclosing the material
terms of the transactions contemplated hereby and in the other Registered Offering Transaction Documents; (iii) the Company has
not and shall not provide material non-public information to the Investor unless prior thereto the Investor shall have executed
a written agreement regarding the confidentiality and use of such information; and (iv) the Company understands and confirms that
the Investor will be relying on the acknowledgements set forth in clauses (i) through (iii) above if the Investor effects any transactions
in the securities of the Company.

 

[Signature page follows]

 

 

    	31  

    	 

    

 

22 Your signature on this Signature Page evidences your agreement
to be bound by the terms and conditions of the Investment Agreement as of the date first written above. The undersigned signatory
hereby certifies that he has read and understands the Investment Agreement, and the representations made by the undersigned in
this Investment Agreement are true and accurate, and agrees to be bound by its terms.

 

GHS INVESTMENTS, LLC

 

By: "AAA

 

Name: Mark Grober Title: Member

 

of INC. By:

 

Name:Arman Tabatabaei Title: CEO

 

[SIGNATURE PAGE OF EQUITY FINANCING AGREEMENT]

 

 

    	32  

    	 

    

 

 

23 EXHIBITA

 

EXHIBIT B

 

EXHIBIT C

 

EXHIBIT D

 

LIST OF EXHIBITS

 

Registration Rights Agreement Notice of Effectiveness Put Notice

 

Put Settlement Sheet

 

24 See attached.

 

    	33  

    	 

    

EXHIBIT A

 

REGISTRATION RIGHTS AGREEMENT

 

 

 

 

    	34  

    	 

    

 

25 EXHIBIT B

 

FORM OF NOTICE OF EFFECTIVENESS OF REGISTRATION STATEMENT

 

Date: 08-07-2020 [TRANSFER AGENT] Re: Cannabis Global, Inc. Ladies
and Gentlemen:

 

We are counsel to Cannabis Global, Inc., a Nevada corporation (the
"Company''), and have represented the Company in connection with that certain Equity Financing Agreement (the "Investment
Agreement") entered into by and among the Company and GHS Investments, LLC(the "Investor'') pursuant to which the Company
has agreed to issue to the Investor shares of the Company's common stock, $ par value per share (the "Common Stock'"')
on the terms and conditions set forth in the Investment Agreement. Pursuant to the Investment Agreement, the Company also has entered
into a Registration Rights Agreement with the Investor (the "Registration Rights Agreement'') pursuant to which the Company
agreed, among other things, to register the Registrable Securities (as defined in the Registration Rights Agreement), including
the shares of Common Stock issued or issuable under the Investment Agreement under the Securities Act of 1933, as amended (the
"1933 Act"). In connection with the Company's obligations under the Registration Rights Agreement, on 50, the Company
filed a Registration Statement on Form S-1 (File No. _4) (the "Registration Statement") with the Securities and Exchange
Commission (the "SEC") relating to the Registrable Securities which names the Investor as a selling shareholder thereunder.

 

In connection with the foregoing, we advise you that a member of
the SEC's staff has advised us by telephone that the SEC has entered an order declaring the Registration Statement effective under
the 1933 Act at on _0 and we have no knowledge, after telephonic inquiry of a member of the SEC's staff, that any stop order suspending
its effectiveness has been issued or that any proceedings for that purpose are pending before, or threatened by, the SEC and the
Registrable Securities are available for sale under the 1933 Act pursuant to the Registration Statement

 

Very truly yours,

 

[Company Counsel]

 

    	35  

    	 

    

 

 

26 EXHIBIT C

 

FORM OF PUT NOTICE

 

Date: RE: Put Notice Number _

 

Dear Mr./Ms.

 

2

 

This is to inform you that as of today, Cannabis Global, Inc.., a
Nevada corporation (the "Company", hereby elects to exercise its right pursuant to the Equity Financing Agreement to
require GHS Investments LLC to purchase shares of its common stock. The Company hereby certifies that:

 

The amount of this put is $

 

The Pricing Period runs from until

The Purchase Price is: $ The number of Put Shares due: The current
number of shares of common stock issued and outstanding is:

 

The number of shares currently available for issuance on the S-1
is:

Regards, Cannabis Global, Inc..

 

By: Name: Title:

 

 

    	36  

    	 

    

 

27 EXHIBIT D PUT SETTLEMENT SHEET Date: Dear Mr. ;

 

Pursuant to the Put given by Cannabis Global, Inc.., to GHS Investments
LLC ("GHS") on 202_, we are now submitting the amount of common shares for you to issue to GHS.

 

Please have a certificate bearing no restrictive legend totaling
shares issued to GHS immediately and send via DWAC to the following account:

 

[INSERT] If not DWAC eligible, please send FedEx Priority Overnight
to: [INSERT ADDRESS] Once these shares are received by us, we will have the funds wired to the Company. Regards,

 

GHS INVESTMENTS LLC By:

 

Name: Title

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]